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Nicotinamide adenine dinucleotide (NAD) is a key regulator of several metabolic and 
signaling pathways that are relevant in cancer cell survival. Cancer cells have an increased 
energy demand associated with an increased NAD turnover. Nicotinamide 
phosphoribosyltransferase (NAMPT), a key enzyme of the NAD salvage pathway, plays a 
crucial role in maintaining the intracellular NAD levels and in regulating the activity of 
NAD-dependent enzymes, such as sirtuins (SIRTs). The inhibition of NAMPT activity and 
the use of phytochemicals, such as resveratrol, represent novel therapeutic approaches in 
cancer therapy. Based on these facts, this thesis aimed to investigate (1) the 
chemotherapeutic potential and molecular mechanisms of FK866, a specific NAMPT 
inhibitor, and resveratrol on hepatocarcinoma cells and to find out whether there are 
differences compared to primary human hepatocytes; (2) to address the impact of NAMPT 
inhibition on the energy metabolism in cancer cells; and (3) to investigate the roles of 
NAMPT and SIRT1 in resveratrol´s mode of action and chemotherapeutic effects. This 
work demonstrates that FK866 and resveratrol possess potent chemotherapeutic effects in 
hepatocarcinoma cells which were absent in human hepatocytes. Hepatocarcinoma cells 
display a dysregulation in the AMP-activated kinase (AMPK)/mammalian target of 
rapamycin (mTOR) signaling as well as in the NAMPT-mediated NAD salvage pathway 
compared to human hepatocytes. FK866-induced NAMPT inhibition induces ATP 
depletion associated with AMPK activation and mTOR inhibition whereas resveratrol 
induces caspase3-mediated apoptosis that is not dependent on NAMPT and SIRT1 
function. NAMPT and SIRT1 are differentially regulated by resveratrol in hepatocarcinoma 
cells and human hepatocytes. This work also reveals that resveratrol activates p53-induced 
cell cycle arrest in hepatocarcinoma cells which is partly mediated by SIRT1 inhibition. In 
summary, this thesis provides new insight into the role of the NAMPT-mediated NAD 
salvage pathway in energy metabolism and characterized FK866 and resveratrol as 
promising potential chemotherapeutic agents for treatment of hepatocellular carcinoma. 
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SUMMARY 
For almost a century it has been known that cancer cells show fundamental differences in 
their central metabolic and signaling pathways compared to non-transformed cells. Already 
in the 1920s, Otto Warburg found that under aerobic conditions, tumor tissue metabolizes 
approximately tenfold more glucose to lactate in a given time than normal tissue. The so-
called Warburg effect describes that cancer cells under normoxic conditions have a high 
glycolytic rate accompanied by reduced oxidative phosphorylation. These findings have 
influenced the scientific community significantly. Today it is known that due to changes in 
central metabolic pathways and rapid cell proliferation cancer cells have an increased 
energy demand compared to normal cells. These metabolic alterations require the redox co-
factor nicotinamide adenine dinucleotide (NAD). Thus, cancer cells have an increased 
NAD turnover due to their need for continuous energy supply. Throughout this thesis, the 
term NAD will be used instead of NAD+ (the oxidized form). 
 Besides its role in cellular redox reactions, NAD plays a pivotal role as substrate for 
NAD-dependent enzymes, such as poly (ADP-ribose) polymerases (PARPs), mono-ADP 
ribosyltransferases (MARTs), ADP-ribosyl cyclases/CD38 and sirtuins. These enzymes 
regulate different biological processes, including transcription, cell cycle progression, 
apoptosis, intracellular calcium mobilization and metabolic pathways – processes that 
undergo fundamental changes during malignant transformation. Thus, NAD has emerged 
as one of the most important links between regulatory and bioenergetic processes. The 
characteristic features of cancer cell metabolism and the importance of the NAD salvage 
pathway in cancer cell biology are described in Chapter 1. NAD-dependent enzymes 
continuously consume NAD and thereby degrade NAD with the concomitant release of 
nicotinamide, which has a negative feedback function. Thus, constant NAD recycling is an 
absolute requirement for cell survival and cell growth, especially for rapidly growing cells. 
The permanent conversion of nicotinamide to NAD is mediated by nicotinamide 
phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the mammalian NAD 
biosynthesis starting from nicotinamide. NAMPT catalyzes that rate limiting step in the 
NAD salvage pathway generating nicotinamide mononucleotide (NMN) which is then 
converted into NAD by isoenzymes of nicotinamide mononucleotide adenylyltransferases 
(NMNATs) 1-3. NAMPT can be found intracellularly (iNAMPT) and extracellularly in 
supernatant and plasma (eNAMPT). Both, intracellular and extracellular NAMPT seem to 
be responsible for its relevance in a variety of human diseases, including cancer 
progression. To maintain intracellular NAD supply tumor cells often overexpress NAMPT. 
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In this context, clinical studies reported increased serum NAMPT levels in cancer patients 
with a positive correlation between either tissues or circulating levels and stage progression.  
NAMPT regulates the activity of NAD-dependent enzymes, such as the deacetylase 
sirtuin 1 (SIRT1). SIRT1 belongs to the class III of histone deacetylases (also called lysine 
deacetylases) and besides histone proteins, SIRT1 also regulates the expression and activity 
of non-histone proteins and transcription factors including p53, forkhead box ‘Other’ 
(FoxO) proteins, hypoxia-inducible factor 2α (HIF-2α), peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha (PGC1-α), Ku70 and others. Thus, SIRT1 is 
implicated in a number of metabolic pathways and biological processes that are important 
in cancer cell metabolism. Several studies postulated a tumor promotor function for 
SIRT1. Additionally, different cancer types including hepatocellular carcinoma (HCC) show 
an increased SIRT1 expression and activity. However, the expression and regulation of 
NAMPT in HCC has not been described so far. HCC is the second leading cause of 
cancer-related deaths worldwide and treatment options are limited. To understand the 
mechanisms of tumor progression is essential for the development of novel therapy 
approaches. Therefore, targeting NAMPT activity and reducing NAD salvage represent a 
promising chemotherapeutic option in HCC cancer therapy.  
The uncontrolled proliferation presents a significant bioenergetic challenge to 
cancer cells. As key physiological energy sensor, AMP-activated protein kinase (AMPK) is a 
major regulator of cellular energy homeostasis that translates changes in glucose availability 
and fluctuation of energy to mammalian target of rapamycin (mTOR). AMPK activation 
has been shown to inhibit cell proliferation and to abrogate growth of HCC xenografts. As 
a conserved serine/threonine protein kinase, mTOR occupies a central role in the 
regulation of proliferation, differentiation, cell growth and angiogenesis. mTOR down-
stream targets are the ribosomal protein S6 kinase (p70S6K) and the eukaryotic translation 
initiation factor 4E (eIF4E) binding protein 1 (4E-BP1), both responsible for protein 
synthesis and cell growth. mTOR suppresses apoptosis and is frequently hyperactivated in 
human cancers. Therefore, a dysregulation of the AMPK/mTOR signaling pathway has 
been assumed to play an essential role in cancer development. Thus, altered metabolism 
has now been recognized as one of the hallmarks of cancer and has thus become an 
attractive target for cancer therapy. Reducing NAMPT activity and intracellular NAD 
content may represent a novel therapeutic concept to influence cellular energy metabolism 
and to regulate the AMPK/mTOR signaling pathway. 
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Furthermore, emerging evidence indicated the use of natural agents as cancer 
therapy. Phytochemicals, such as resveratrol, have received increasing attention as they 
exert chemopreventive and chemotherapeutic potential. In different screening assays as 
well as in animal studies, resveratrol has been shown to activate AMPK and SIRT1. 
However, further studies argued whether resveratrol activates SIRT1 directly or not. 
Additionally, the role of NAMPT in the chemotherapeutic action of resveratrol in cancer 
cells was not yet known at the beginning of this thesis.  
Based on these facts, the hypothesis was proposed that targeting NAMPT activity 
by pharmacological inhibition reduces cell viability of hepatocarcinoma cells. Therefore, 
the aims of my thesis were (1) to investigate the chemotherapeutic potential and molecular 
mechanisms of the polyphenol resveratrol  and of FK866, a specific NAMPT inhibitor, on 
hepatocarcinoma cells and to find out whether there are differences compared to non-
cancerous primary human hepatocytes; (2) to address the impact of a pharmacological 
NAMPT inhibition on the energy metabolism and the AMPK/mTOR pathway in 
hepatocarcinoma cells and human hepatocytes; and (3) to investigate the functional roles 
of NAMPT and SIRT1 in resveratrol´s mode of action and chemotherapeutic effects and 
to compare them between both cell models (hepatocarcinoma cells and primary human 
hepatocytes). The results obtained in my thesis provide new insight into the role of the 
NAMPT-mediated NAD salvage pathway in cancer cell metabolism and the underlying 
molecular mechanisms of FK866 and resveratrol in hepatocarcinoma cells.  
Chapter 2 gives an overview of the physiological and pathophysiological functions 
of NAMPT and its relevance in different diseases.  
The experimental study presented in Chapter 3 aimed at investigating the effects of 
a pharmacological NAMPT inhibition by FK866 on cancer cell viability and asked whether 
NAD depletion induces energy stress that may activate AMPK and downregulate mTOR 
signaling. It also targeted the question whether non-cancerous human hepatocytes are less 
sensitive to a NAMPT inhibition than cancer cells. To determine whether the observed 
FK866 effects are dependent on NAMPT enzymatic function, the cells were co-stimulated 
with the NAMPT enzyme product, NMN, to reverse cellular NAD depletion. First, we 
aimed to identify differences in the energy metabolism in hepatocarcinoma cells and human 
hepatocytes and found that AMPK was significantly less activated in hepatocarcinoma cells 
compared to non-cancerous human hepatocytes. In contrast components of the mTOR 
complex1 (mTORC1) cascade, such as mTORC1, p70S6K and 4E-BP1, were higher 
expressed in hepatocarcinoma cells than in human hepatocytes. This supports the 
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hypothesis that a dysregulation of the AMPK/mTOR pathway may contribute to the 
development of HCC. 
In further analysis, the effects of a FK866-mediated NAMPT inhibition on energy 
metabolism and cell viability of hepatocarcinoma cells and human hepatocytes were 
studied. We could show that FK866 rapidly reduced NAD levels and led to delayed cell 
death after 72h associated with ATP depletion in hepatocarcinoma cells. Furthermore, 
FK866-induced NAD reduction led to a decreased activity of NAD-dependent lysine 
deacetylases as measured by an increased global acetylation of protein lysine residues by 
immunoblot. In subsequent analysis, FK866-treated hepatocarcinoma cells displayed 
increased AMPK activation and inhibition of mTOR signaling. The co-administration of 
NMN abrogated the effects of FK866 on cell viability and on the AMPK/mTOR signaling 
pathway suggesting that these effects were mediated by reduced NAMPT enzymatic 
function. Interestingly, the same concentration of FK866 used in hepatocarcinoma cells did 
not affect NAD production and the AMPK/mTOR signaling cascade in non-cancerous 
human hepatocytes indicating a reduced sensitivity of non-cancerous cells to FK866. In 
summary, FK866 induced delayed cell death in hepatocarcinoma cells by reducing the 
cellular ATP level, activating AMPK and downregulating mTOR signaling. The results of 
this work also suggest that FK866 has low cytotoxic effects on primary hepatocytes. 
The polyphenol resveratrol has been described to possess chemotherapeutic 
properties in different cancer types including HCC. In Chapter 4, we investigated the 
molecular mechanisms of resveratrol and attempted to identify the relevance of NAMPT 
and SIRT1 protein function in resveratrol´s mode of action in hepatocarcinoma cells and in 
human hepatocytes. We asked whether NAMPT and SIRT1 are involved in resveratrol´s 
chemotherapeutic function. Resveratrol decreased cell viability and selectively induced p53 
phosphorylation in hepatocarcinoma cells but not in human hepatocytes. Further, 
moderate doses of resveratrol led to cell cycle arrest in the S- and G2/M-phase of 
hepatocarcinoma cells in a p53-dependent manner. In addition, p53-deficient 
hepatocarcinoma cells did not show changes in cell cycle distribution but were more 
sensitive to apoptosis induction by resveratrol than p53 wild-type hepatocarcinoma cells. 
Resveratrol induced caspase-3-mediated apoptosis in all hepatocarcinoma cell lines 
indicating that resveratrol-induced apoptotic effects did not depend on p53 function. 
Measuring the basal expression of NAMPT and SIRT1, we found that both proteins were 
oppositely expressed in hepatocarcinoma cells and human hepatocytes. In particular, 
hepatocarcinoma cells expressed lower levels of NAMPT mRNA and protein compared to 
human hepatocytes. However, despite lower NAMPT protein levels, hepatocarcinoma cells 
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possessed higher basal NAMPT activity than non-cancerous hepatocytes. In contrast, the 
NAD-dependent deacetylase SIRT1 was significantly higher expressed in hepatocarcinoma 
cells compared to human hepatocytes.  
In subsequent studies, we investigated the functional roles of NAMPT and SIRT1 
in resveratrol´s mode of action in human hepatocytes and hepatocarcinoma cells. The 
present study could demonstrate that resveratrol positively regulated NAMPT activity and 
NAD production in non-cancerous human hepatocytes without affecting NAMPT protein 
expression, thus indicating beneficial substrate conditions for NAD-dependent enzymes. It 
may be assumed that post-translational modifications of the NAMPT protein play a role in 
NAMPT´s enzymatic regulation and that resveratrol potentially influences such reactions.  
Interestingly, in contrast to our findings in human hepatocytes, NAMPT activity 
and SIRT1 protein expression were negatively regulated by resveratrol in hepatocarcinoma 
cells. High doses of resveratrol reduced NAMPT enzymatic activity and increased NAMPT 
release. The release of NAMPT into the supernatant was time-dependent and associated 
with increased NAMPT mRNA expression levels, suggesting a compensatory mechanism 
to maintain stable NAMPT protein levels. It is conceivable, that the resveratrol-mediated 
NAMPT mRNA induction and NAMPT release are induced as a stress-response reaction. 
Recent studies support this hypothesis as they found that different stress signals induced 
NAMPT gene expression and increased NAMPT serum levels. 
Furthermore, resveratrol-treated hepatocarcinoma cells displayed reduced SIRT1 
protein levels. SIRT1 targets and deacetylates the tumorsuppressor protein p53, thus 
leading to its inhibition and promoting tumorigenesis. We could demonstrate, that 
hepatocarcinoma cells treated with resveratrol showed increased p53 acetylation at lysine 
residue 382 (K382), a main target site of SIRT1, indicating a potentially reduced SIRT1 
activity in these cells. p53 hyperacetylation leads to its transcriptional activation and 
induction of the downstream target p21/WAF1/Cip1 which was significantly increased in 
hepatocarcinoma cells in our study. To investigate whether the effects of resveratrol were 
mediated by the observed reduced NAMPT activity and NAD synthesis, cells were co-
treated with the NAMPT enzymatic product, NMN. Interestingly, NMN did not 
ameliorate resveratrol-induced cell cycle arrest and apoptosis suggesting that the availability 
of NMN or NAD were not limiting factors in this scenario. To find out whether the 
reduced SIRT1 protein function was involved in the cellular effects of resveratrol in 
hepatocarcinoma cells, experiments on SIRT1 overexpression were performed. Our results 
revealed that a SIRT1 overexpression significantly decreased the resveratrol-induced cell 
20  SUMMARY 
cycle arrest by reducing p53 acetylation (K382) but failed to abrogate resveratrol-induced 
apoptosis. This suggests an important role for SIRT1 in p53-induced cell cycle regulation 
but not in apoptotic mechanisms. Furthermore, increased SIRT1 expression also reversed 
resveratrol-induced NAMPT release. This indicates a regulatory function for SIRT1 in the 
mechanism of NAMPT secretion whereas the underlying mechanisms are not known.  
To conclude this study, resveratrol positively regulated NAMPT activity and NAD 
levels in non-cancerous human hepatocytes but negatively influenced NAMPT and SIRT1 
protein function in hepatocarcinoma cells. Further, SIRT1 was shown to be involved in 
p53-mediated cell cycle arrest and NAMPT secretion. However, neither NAMPT nor 
SIRT1 were involved in the resveratrol-mediated apoptotic effects on hepatocarcinoma 
cells. Thus, several collective activities, rather than just a single effect, may account for the 
anticancer properties of resveratrol.  
 
In summary, this work demonstrates that a FK866-induced NAMPT inhibition 
reduces the cell viability of hepatocarcinoma cells and shows the importance of the 
NAMPT-mediated NAD salvage pathway for the energy metabolism in cancer cells. These 
results verify that hepatocarcinoma cells due to a higher basal NAMPT activity are more 
sensitive to a FK866-mediated NAMPT inhibition than non-cancerous human hepatocytes. 
Resveratrol was shown to reduce NAMPT and SIRT1 activity associated with an increased 
cell cycle arrest selectively in hepatocarcinoma cells as compared to non-cancerous human 
hepatocytes.  
This thesis contributes to a better understanding of the molecular mechanisms and 
potential therapeutic functions of FK866 and resveratrol in the pathogenesis of 
hepatocellular carcinoma. 
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ZUSAMMENFASSUNG 
Die unkontrollierte Teilung von Krebszellen stellt eine große Herausforderung an deren 
Energiestoffwechsel dar. In Folge dessen kommt es in Krebszellen zu gravierenden 
Veränderungen in verschiedenen Signal-und Stoffwechselwegen. Bereits 1924 konnte Otto 
Warburg zeigen, dass Tumorgewebe trotz aerober Bedingungen 10-mal so viel Glukose zu 
Laktat umsetzt als gesundes Gewebe. Warburg nannte diesen Effekt aerobe Glykolyse. Das 
bedeutet, dass Krebszellen auch in Anwesenheit von genügend Sauerstoff einen 
ausgeprägten glykolytischen Stoffwechsel besitzen und eine verminderte oxidative 
Phosphorylierung. Der veränderte Stoffwechsel sowie die gesteigerte Zellteilung und 
Proliferation führt in Krebszellen zu einem deutlich höheren Energiebedarf. Um diesen 
außerordentlichen Energiebedarf zu decken, sind Krebszellen auf eine kontinuierliche 
Verfügbarkeit des Redox-Kofaktors Nikotinamidadenindinukleotid (NAD) angewiesen 
und besitzen daher einen deutlich höheren NAD Umsatz als normale Zellen. In dieser 
Arbeit wird die Bezeichnung NAD anstelle von NAD+ verwendet. 
 Neben seiner Tätigkeit als Koenzym bei Redox-Reaktionen besitzt NAD ebenfalls 
eine wichtige Funktion als Substrat von NAD-abhängigen Enzymen, wie z.B Poly-(ADP-
ribose)-Polymerasen (PARPs), Mono-ADP-Ribosyltransferasen (MARTs), ADP-
Ribosylcyclasen/CD38 und Sirtuinen (SIRTs). NAD-abhängige Enzyme sind an der 
Regulation verschiedener Stoffwechselprozesse beteiligt und spielen eine wichtige Rolle 
unter anderem bei der Transkription, dem Zellzyklus und der Apoptose – Prozesse, die 
besonders während der Tumorgenese wesentlichen Veränderungen unterliegen. Die 
charakteristischen Veränderungen im Stoffwechsel von Krebszellen sowie die Bedeutung 
von NAD werden in Kapitel 1 dieser Arbeit erläutert. 
 NAD wird kontinuierlich von NAD-abhängigen Enzymen verbraucht, indem sie 
NAD abbauen und gleichzeitig Nikotinamid freisetzen. Daher ist die ständige 
Wiedergewinnung von NAD aus Nikotinamid besonders für Krebszellen von Bedeutung, 
da es das Zellüberleben und Krebswachstum sichert. Die permanente Umwandlung von 
Nikotinamid zu NAD wird durch die Nikotinamidphosphoribosyltransferase (NAMPT), 
einem Schlüsselenzym der NAD-Biosynthese, vermittelt. NAMPT synthetisiert 
Nikotinamid-Mononukleotid (NMN), welches danach durch die Isoenzyme Nikotinamid-
Mononukleotid-Adenylyltransferase (NMNAT) 1-3 weiter zu NAD umgewandelt wird. 
NAMPT konnte sowohl intrazellulär (iNAMPT) als auch extrazellulär bzw. im Plasma 
(eNAMPT) nachgewiesen werden. Jedoch sind die strukturellen Unterschiede beider 
Formen bis heute nicht bekannt. Man geht aber davon aus, dass die unterschiedlichen 
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Funktionen von eNAMPT und iNAMPT bei der Entstehung verschiedener Krankheiten, 
auch bei der Tumorprogression, eine Rolle spielen. Um eine kontinuierliche NAD-
Versorgung zu gewährleisten, wird NAMPT in Krebszellen häufig überexprimiert. 
Klinische Studien zeigten, dass der NAMPT-Serumspiegel in Krebspatienten nicht nur 
erhöht war, sondern auch mit dem Grad der Tumorerkrankung korrelierte. 
 Als NAD-produzierendes Enzym reguliert NAMPT die Aktivität NAD-abhängiger 
Enzyme, beispielsweise der Deacetylase Sirtuin 1 (SIRT1). Obwohl SIRT1 zu der Klasse 
III der Histon-Deacetylasen (auch Lysin-Deacetylasen genannt) gehört, reguliert es neben 
Histon-Proteinen auch die Expression und Aktivität von Nicht-Histon-Proteinen und 
Transkriptionsfaktoren, wie z.B. p53, Proteine der forkhead box ‘Other’ (FoxO) Familie, 
hypoxia-inducible factor 2α (HIF-2α), peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC1-α) und Ku70. Damit beeinflusst SIRT1 eine Vielzahl von Stoffwechselwegen 
und biologischen Prozessen, die vor allem während der Tumorentstehung von Bedeutung 
sind. In verschiedenen Tumorgeweben, unter anderem auch im hepatozellulären Karzinom 
(HCC), konnte eine verstärkte SIRT1-Expression nachgewiesen werden. Die Expression 
und Regulation von NAMPT im HCC-Gewebe ist jedoch nicht bekannt. Das HCC gehört 
zu der weltweit zweithäufigsten Krebs-Todesursache und dessen 
Behandlungsmöglichkeiten sind derzeit sehr begrenzt. Daher ist das Verständnis der 
molekularen Mechanismen der Tumorgenese essentiell für die Entwicklung neuer 
Therapieansätze. Die Inhibierung der NAMPT-Enzymaktivität stellt eine vielversprechende 
neue Therapieoption bei der Behandlung des HCCs dar.  
Der zelluläre Energiehaushalt wird maßgeblich durch die AMP-aktivierte 
Proteinkinase (AMPK) reguliert. Als physiologischer Sensor übermittelt die AMPK 
Veränderungen in der Glukoseverfügbarkeit und Schwankungen im Energiehaushalt an das 
mammalian target of rapamycin (mTOR). Die Aktivierung der AMPK zeigte in mehreren 
Studien eine anti-proliferative Wirkung und verminderte das Krebswachstum in HCC-
Xenograft-Tieren. Als hochkonservierte Serin/Threonin-Proteinkinase spielt mTOR eine 
wichtige Rolle in der Regulation von Proliferation, Differenzierung und Vermehrung der 
Zelle. mTOR kontrolliert dabei die Translation von Proteinen und Transkriptionsfaktoren 
und sichert somit das Zellüberleben. Zu seinen Zielmolekülen gehört unter anderem die 
ribosomale S6 Proteinkinase (p70S6K) und das eukaryotische Translationsinitiationsfaktor 
4E (eIF4E) Bindeprotein1 (4E-BP1). Über diese Signalkaskade kommt es zur Stimulation 
der Proliferation, des Zellwachstums und der Angiogenese sowie zur Unterdrückung der 
Apoptose. In Folge dessen ist mTOR in malignen Tumoren häufig überaktiviert und gilt 
daher als interessantes und vielversprechendes Zielprotein in der Krebstherapie. Man 
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vermutet, dass eine Dysregulation des AMPK/mTOR-Signalwegs eine essentielle Rolle bei 
der Krebsentstehung und bei der Tumorprogression spielt. Die pharmakologische 
Inhibierung der NAMPT-Enzymaktivität und die damit verbundene Reduzierung der 
intrazellulären NAD-Spiegel stellen einen neuen Ansatzpunkt in der Krebstherapie dar, um 
den Energiehaushalt der Krebszelle zu beeinflussen und den AMPK/mTOR-Signalweg zu 
regulieren.  
Darüber hinaus erregten in den letzten Jahren sekundäre Pflanzenstoffe, wie z.B. 
Resveratrol, in der Krebsforschung großes wissenschaftliches Interesse. So überzeugte 
Resveratrol in verschiedenen Versuchsmodellen sowohl mit seiner chemopräventiven als 
auch mit seiner chemotherapeutischen Wirksamkeit. In verschiedenen in vitro 
Screeningassays sowie in verschiedenen Tiermodellen wurde Resveratrol als natürlicher 
Aktivator von AMPK und SIRT1 identifiziert. Zahlreiche Studien folgten, die die SIRT1-
aktivierende Wirkung von Resveratrol zum Thema hatten, jedoch aber widersprüchliche 
Ergebnisse hervorbrachten. Daher ist umstritten, ob Resveratrol SIRT1 direkt reguliert 
oder indirekt durch z.B. eine Erhöhung des zellulären NAD-Spiegels. Zudem war zu 
Beginn dieser Arbeit nicht bekannt, welche Rolle NAMPT in der chemotherapeutischen 
Wirkung von Resveratrol auf Hepatokarzinomzellen spielt.  
 Basierend darauf, stellte ich die Hypothese auf, dass eine Inhibierung der NAMPT-
Enzymaktivität die Viabilität von Hepatokarzinomzellen vermindert. Um diese Hypothese 
zu prüfen, sollten in der vorliegenden Arbeit (1) die chemotherapeutische Wirkung von 
Resveratrol sowie die molekularen Mechanismen von FK866, einem NAMPT-spezifischen 
Inhibitor, in Hepatokarzinomzellen und nicht-kanzerogenen primären humanen 
Hepatozyten untersucht werden. Zudem sollte (2) die Frage beantwortet werden, ob eine 
NAMPT-Inhibition den Energiehaushalt und den AMPK/mTOR-Signalweg beeinflusst 
und ob Hepatokarzinomzellen sensitiver auf eine NAMPT-Inhibierung reagieren als 
normale Hepatozyten. In weiteren Analysen sollte (3) die Funktion von NAMPT und 
SIRT1 in der Wirkungsweise von Resveratrol untersucht und in beiden Zellmodellen 
(Hepatokarzinomzellen und humane Hepatozyten) verglichen werden. Die Ergebnisse 
dieser Arbeit tragen zu einem besseren Verständnis der pharmakologischen NAMPT-
Inhibition im Krebsstoffwechsel bei und geben Aufschluss über die molekularen 
Mechanismen der chemotherapeutischen Wirkung von FK866 und Resveratrol in 
Hepatokarzinomzellen. 
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 Ein Überblick über die physiologischen und pathophysiologischen Funktionen von 
NAMPT sowie seine Relevanz bei diversen Erkrankungen wird in Kapitel 2 dieser Arbeit 
gegeben. 
 Kapitel 3 dieser Arbeit beschäftigt sich mit den Auswirkungen einer 
FK866-vermittelten NAMPT-Inhibierung auf den Energiehaushalt und das Zellwachstum 
von Hepatokarzinomzellen. Dafür untersuchten wir zunächst basale Unterschiede im 
Energiestoffwechsel von Hepatokarzinomzellen und humanen Hepatozyten. In diesem 
Zusammenhang zeigten Hepatokarzinomzellen eine verminderte AMPK-Aktivierung sowie 
eine deutlich höhere Aktivität des mTOR-Komplex-1-Signalwegs. Diese Ergebnisse 
unterstützen die Annahme, dass eine Dysregulation des AMPK/mTOR-Signalwegs bei der 
Entstehung des HCC eine wichtige Rolle spielt. 
In weiteren in-vitro Analysen untersuchten wir die Effekte der pharmakologischen 
NAMPT-Inhibierung auf die Viabilität und den Energiestoffwechsel von 
Hepatokarzinomzellen und verglichen sie mit denen in humanen Hepatozyten. Die 
Behandlung der Hepatokarzinomzellen mit FK866 führte zu einer raschen Senkung des 
zellulären NAD-Spiegels sowie zu einem verzögerten Eintritt des Zelltods nach 72h, der 
mit einer Reduktion des zellulären ATP-Spiegels korrelierte. Zugleich zeigten die FK866-
behandelten Zellen eine verminderte Aktivität von NAD-abhängigen Deacetylasen, was zu 
einem Anstieg der Acetylierung von Lysinresten an Proteinen führte. In weiteren Analysen 
führte die FK866-induzierte NAD-Abnahme zur Aktivierung der AMPK und zur 
Hemmung des mTOR-Signalwegs in Hepatokarzinomzellen. Um festzustellen, ob die 
FK866-vermittelten Effekte von der NAMPT-Enzymaktivität abhängig sind, wurden die 
Zellen mit FK866 und dem NAMPT-Enzymprodukt NMN ko-stimuliert. Die Ergebnisse 
zeigten, dass die Zugabe von NMN nicht nur die Effekte auf den AMPK/mTOR-
Signalweg, sondern auch auf den FK866-induzierten Zelltod, aufheben konnten. Damit 
konnte nachgewiesen werden, dass die zellulären Effekte von FK866 durch eine 
verminderte NAMPT-Enzymaktivität vermittelt werden. Interessanterweise zeigten 
humane Hepatozyten, die unter den gleichen Bedingungen mit FK866 behandelt wurden, 
keine signifikanten Veränderungen in ihrem NAD-Spiegel oder im AMPK/mTOR-
Signalweg. Dies macht deutlich, dass primäre Hepatozyten eine geringere Sensitivität 
gegenüber FK866 aufweisen. Zusammenfassend konnten diese Ergebnisse belegen, dass 
eine FK866-induzierte NAMPT-Inhibierung zu einer Reduzierung der Viabilität von 
Hepatokarzinomzellen führte. Dies war mit einem Abfall des zellulären ATP-Spiegels und 
der Aktivierung der AMPK und Hemmung des mTOR-Signalwegs assoziiert. Des 
ZUSAMMENFASSUNG  25 
Weiteren bestätigten diese Ergebnisse, dass Hepatokarzinomzellen sensitiver auf eine 
NAMPT-Inhibierung reagieren als primäre Hepatozyten.  
 Der sekundäre Pflanzenstoff Resveratrol konnte bereits in unterschiedlichen in 
vitro und in vivo Studien sowohl seine chemopräventive als auch chemotherapeutische 
Wirkung zeigen. Kapitel 4 dieser Arbeit gibt Aufschluss über die molekulare 
Wirkungsweise von Resveratrol in Hepatokarzinomzellen und primären Hepatozyten und 
geht der Frage nach welche Rolle NAMPT und SIRT1 bei der chemotherapeutischen 
Wirkung von Resveratrol spielen. 
 Die Ergebnisse dieser Arbeit zeigten, dass Resveratrol die Viabilität von 
Hepatokarzinomzellen signifikant reduzierte und zu einer verstärkten Phosphorylierung 
von p53 führte. Moderate Dosen dieses Polyphenols induzierten einen p53-abhängigen 
Zellzyklusarrest in der S- und G2/M-Phase in Hepatokarzinomzellen. In p53-defizienten 
Hepatokarzinomzellen konnte hingegen keine Veränderung im Zellzyklus festgestellt 
werden. Jedoch induzierte Resveratrol in diesen Zellen stärker Apoptose als in p53-Wildtyp 
Hepatokarzinomzellen. Zudem führte Resveratrol in allen Hepatokarzinomzelllinien zu 
einer Caspase-3-vermittelten Apoptose, was darauf hindeutet, dass die Resveratrol-
induzierte apoptotische Wirkung p53-unabhängig vermittelt wird. Beim Vergleich der 
Expression von NAMPT und SIRT1 in Hepatokarzinomzellen und humanen Hepatozyten 
zeigte sich, dass beide Proteine gegensätzlich exprimiert wurden. So wiesen 
Hepatokarzinomzellen eine signifikant verminderte NAMPT-mRNA- und NAMPT-
Protein-Expression gegenüber humanen Hepatozyten auf. Interessanterweise besaßen 
jedoch die Hepatokarzinomzellen, trotz niedrigerer NAMPT-Proteinspiegel, eine höhere 
basale NAMPT-Enzymaktivität als humane Hepatozyten. Die Expression der Deacetylase 
SIRT1 zeigte hingegen eine signifikant stärkere Expression in Hepatokarzinomzellen als in 
primären Hepatozyten.  
 In weiteren Experimenten sollte untersucht werden, welche Funktion NAMPT 
und SIRT1 in der Wirkungsweise von Resveratrol in Hepatokarzinomzellen und humanen 
Hepatozyten haben und ob sie eine Rolle bei dessen chemotherapeutischer Wirkung 
spielen. Wir konnten zeigen, dass Resveratrol in primären Hepatozyten einen positiven 
Effekt auf die NAMPT-Aktivität und die damit verbundenen zellulären NAD-Spiegel 
ausübte, ohne die intrazellulären NAMPT-Proteinspiegel zu beeinflussen. Es ist daher 
anzunehmen, dass Resveratrol eventuell zu post-translationalen Veränderungen am 
NAMPT-Protein führt, die die Enzymaktivität beeinflussen.  In Hepatokarzinomzellen 
hingegen führte die Resveratrol-Behandlung zu einer verminderten NAMPT-
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Enzymaktivität sowie zu einer verstärkten Freisetzung von NAMPT in den Zellüberstand. 
Die vermehrte NAMPT-Freisetzung war mit einer erhöhten NAMPT-mRNA-Expression 
assoziiert, was auf eine kompensatorische Funktion zur Aufrechterhaltung der 
intrazellulären NAMPT-Proteinspiegel hindeutet. Es ist daher anzunehmen, dass NAMPT 
verstärkt als Stressantwort von den Zellen exprimiert und freigesetzt wird. Aktuelle Studien 
unterstützen diese Annahme. Sie konnten zeigen dass verschiedene Arten von Zellstress 
die NAMPT-Genexpression induzieren und die NAMPT-Serumspiegel beeinflussen. Des 
Weiteren führte eine Behandlung mit Resveratrol in Hepatokarzinomzellen zu einem 
verminderten SIRT1-Proteinspiegel. Eines der wichtigsten SIRT1-Zielproteine ist das 
Tumorsuppressorprotein p53. Es wird von SIRT1 direkt gebunden und NAD-abhängig am 
Lysinrest 382 (K382) deacetyliert. Dies führt zu einer Inhibierung der transkriptionellen 
Aktivität von p53 und damit zu einer Förderung der Tumorgenese. Unsere Ergebnisse 
zeigten, dass die durch Resveratrol-Behandlung verminderte SIRT1-Proteinexpression mit 
einem Anstieg der Acetylierung von p53 (K382) in Hepatokarzinomzellen assoziiert war. 
Die daraus resultierende verstärkte transkriptionelle Aktivität von p53 wurde anhand der 
erhöhten Expression von p21/WAF1/Cip1 nachgewiesen. Diese Ergebnisse belegen, dass 
Resveratrol die NAMPT- und SIRT1-Proteinfunktion in Hepatokarzinomzellen negativ 
beeinflusst. 
 Um festzustellen, ob die Effekte von Resveratrol durch die verminderte NAMPT-
Enzymaktivität vermittelt sind, wurden die Zellen mit dem NAMPT-Enzymprodukt NMN 
ko-stimuliert. Die Ergebnisse zeigten jedoch, dass NMN keine protektive Wirkung auf die 
Resveratrol-vermittelten Effekte, wie Zellzyklusarrest und Apoptose, ausübte. Dies macht 
deutlich, dass die Verfügbarkeit von NMN und NAD nicht den entscheidenden Faktor in 
der Wirkungsweise von Resveratrol darstellt. Mittels SIRT1-Überexpression sollte 
anschließend herausgefunden werden, ob die Effekte von Resveratrol durch eine 
verminderte SIRT1-Funktion in Hepatokarzinomzellen vermittelt wurden. Doch auch eine 
SIRT1-Überexpression konnte keinen protektiven Effekt auf die Resveratrol-induzierte 
Apoptose in Hepatokarzinomzellen ausüben. Jedoch konnten die Ergebnisse zeigen, dass 
eine verstärkte SIRT1-Expression den Resveratrol-induzierten Zellzyklusarrest sowie die 
p53-Hyperacetylierung reduzieren konnte. Es ist daher anzunehmen, dass SIRT1 eine Rolle 
bei dem p53-vermittelten Zellzyklusarrest, aber nicht bei der Resveratrol-vermittelten 
Apoptose, spielt. Zudem konnte die Resveratrol-induzierte NAMPT-Freisetzung durch 
eine SIRT1-Überexpression aufgehoben werden, was auf einen Zusammenhang zwischen 
der SIRT1-Aktivität und der Regulation der NAMPT-Sekretion hindeutet. Insgesamt 
konnten die Ergebnisse dieser experimentellen Studie zeigen, dass Resveratrol die 
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NAMPT-vermittelte NAD-Biosynthese in humanen Hepatozyten verstärkte und darauf 
aufbauend die Aktivität von SIRT1 positiv beeinflussen könnte. Hingegen führte die 
Behandlung von Hepatokarzinomzellen mit Resveratrol zu einer verminderten NAMPT- 
und SIRT1-Proteinfunktion, was mit einem p53-vermittelten Zellzyklusarrest assoziert war. 
Jedoch wurde festgestellt, dass weder NAMPT noch SIRT1 an der Apoptose-
induzierenden Wirkung von Resveratrol beteiligt sind. Vielmehr könnte eine kollektive 
Wirkung verschiedener Signalwege für die Resveratrol-vermittelte Apoptose-Induktion in 
Krebszellen verantwortlich sein.  
 
Zusammenfassend zeigen die Ergebnisse dieser Arbeit, dass eine FK866-
vermittelte NAMPT-Inhibierung zu einer Reduktion der Viabilität von 
Hepatokarzinomzellen führt und die NAMPT-vermittelte NAD-Biosynthese eine 
bedeutende Rolle im Energiestoffwechsel von Krebszellen spielt. Zudem belegt diese 
Arbeit, dass FK866 in Hepatokarzinomzellen eine deutlich höhere chemotherapeutische 
Wirksamkeit besitzt als in normalen Hepatozyten, was unter anderem auf eine erhöhte 
basale NAMPT-Aktivität in Hepatokarzinomzellen zurückzuführen ist. Resveratrol bewirkt 
in Hepatokarzinomzellen, im Gegensatz zu normalen primären Hepatozyten, eine 
verminderte Aktivität von NAMPT und SIRT1, was mit einem Zellzyklusarrest in der S- 
und G2/M-Phase assoziiert ist. 
Diese Ergebnisse tragen zu einem besseren Verständnis der molekularen 
Wirkungsweise von FK866 und Resveratrol in Hepatokarzinomzellen bei und identifizieren 
somit diese Stoffe als interessante potentielle Wirkstoffkandidaten in der Therapie des 
hepatozellulären Karzinoms. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1 Cancer cell metabolism 
During the past century cancer research has focused on the altered cellular metabolism and 
metabolic regulation that are linked to cancer progression. In normal cells, energy 
transduction leads to the oxidation of nutrients via oxidative phosphorylation. Pyruvate is 
continuously generated via glycolysis and preferentially transported into mitochondria 
where it is further metabolized via the tricarboxylic acid cycle (TCA) to generate reduced 
electron carriers (nicotinamide adenine dinucleotide hydrate (NADH) and flavin adenine 
dinucleotide dihyrdate (FADH2)). They are reconverted to NAD
+ and FAD by oxidative 
phosphorylation through the electron-transport chain (complexes I-IV) in the 
mitochondrial matrix, leading to ATP production by ATP synthase (complex V). In this 
thesis, the term NAD will be used instead of NAD+ (oxidized form). 
It may not be surprising that tumor cells, in order to meet the increased 
requirements of proliferation, often display fundamental changes in pathways of energy 
metabolism and nutrient uptake [1] (Figure 1). In 1924, Otto Warburg found that under 
aerobic conditions, tumor tissue metabolizes approximately tenfold more glucose to lactate 
in a given time than normal tissue. The so-called Warburg effect describes the glycolytic 
switch by which cancer cells consume high amounts of glucose for aerobic glycolysis, but 
only a small portion for oxidative phosphorylation (respiration) even in the presence of 
sufficient oxygen [2]. It is still a matter of debate why cancer cells switch to less-efficient 
ATP generation from aerobic glycolysis rather than from oxidative phosphorylation in 
mitochondria. However, one explanation is that increased glycolysis leads to elevated 
glycolytic intermediates into intersecting biosynthetic pathways, generating amino acids and 
nucleosides required for building macromolecules [3]. Work in recent years has revealed 
that the glycolytic switch is promoted by oncogenes and inhibited by tumor suppressors, 
indicating that it is intrinsically associated with oncogenic transformation [4, 5]. However, 
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normal cells also undergo a glycolytic switch and other metabolic changes to proliferate, 
such as activated T lymphocytes [6]. 
Figure 1. Cancer cell metabolism (the Warburg effect). Comparison of cell metabolism in 
normal cells (left side) and malignant cells (right side). Normal cells prefer the oxidation of 
nutrients via oxidative phosphorylation. The glycolysis continuously generates pyruvate (Pyr) which 
is preferentially transported to the mitochondria and metabolized via the tricarboxylic acid (TCA) 
cycle. In cancer cells, even under normoxic conditions, a high rate of glycolysis and glucose uptake 
is observed while respiration remains almost unchanged (aerobic glycolysis). The lactate 
dehydrogenase isoform A (LDHA) in tumor cells converts accumulated pyruvate to lactate, thereby 
regenerating NAD from NADH for glycolysis. Excess lactate is secreted and contributes to an 
extracellular environment that promotes tumor progression. Glycolytic intermediates are mostly 
diverted into the pentose phosphate pathway (PPP). As a result, NADPH is produced to counteract 
oxidative stress and to build up macromolecules including the production of ribose-5-phosphate 
(Rib-5-P) for nucleic acid synthesis. Hypoxia inducible factor 1α (HIF-1α) supports the glycolytic 
flux and tumor survival. Other abbreviations: PKM1 and 2 (Pyruvate kinase 1 and 2), ROS (reactive 
oxygen species). [7]  
 
In recent years, meta-analysis of published microarray data sets uncovered 
metabolic pathways that are commonly up-regulated across tumor types, namely glycolysis, 
nucleotide synthesis and the pentose phosphate pathway [8]. It has also become clear that 
the cancer specific alterations in signaling pathways are affected by mutations and the 
tumor microenvironment [3, 5]. Furthermore, since the 1950s cancer biologists have also 
recognized the importance of glutamine as a tumor nutrient. Glutamine is involved in 
pivotal mechanisms necessary for proliferating tumor cells. For example, it participates in 
bioenergetics, supports cell defenses against oxidative stress, and complements glucose 
metabolism in the production of macromolecules [9]. Thus, glutamine shares characteristics 
with glucose by fulfilling the two important needs of proliferating cancer cells - ATP 
production and the provision of intermediates for biomass production. 
CHAPTER 1  31 
Glycolytic intermediates are also utilized by growing cells to produce fatty acids and 
non-essential amino acids. Therefore, enhanced glycolysis and de novo fatty acid synthesis 
are indeed characteristic features of cancer cells [10, 11]. This preferred ATP production 
via increased glycolysis rather than oxidative phosphorylation in cancer cells requires 
several metabolic alterations, among them increased amounts of the redox co-factors NAD 
or NAD phosphate (NADP). The lactate dehydrogenase isoform A (LDHA) in tumor cells 
converts accumulated pyruvate to lactate, thereby regenerating NAD from NADH for 
glycolysis. Lactate activates the transcription factor hypoxia-inducible factor-1 α (HIF-1α) 
which stimulates the expression of glycolytic transporters and enzymes supporting high 
rate of glycolysis [12].  
 
1.2 NAD - a key determinant of cancer cell biology 
As the redox couple NAD/NADH, NAD plays a crucial role in numerous cellular 
processes. Within glycolysis and TCA cycle, NAD functions as electron recipient, whereas 
in mitochondrial oxidative phosphorylation NADH is essential as an electron donor for the 
generation of ATP. NAD can also be converted to NADP and reduced to NADPH, which 
is necessary for fatty acid synthesis and anti-oxidant defense. It is important to note that 
NADP-dependent processes are linked to the NAD status as NADP synthesis requires 
NAD. Thus, a depletion of cellular NAD may compromise NADP levels [13].  
Besides its role in cellular redox reactions, NAD also serves as substrate for NAD-
dependent enzymes, such as poly (ADP-ribose) polymerases (PARPs), mono-ADP-
ribosyltransferases (MARTs), ADP-ribosyl cyclases/CD38 and sirtuins [13, 14]. It is 
therefore one of the most important links between regulatory and bioenergetic processes 
(Figure 2).  
NAD-mediated signaling events are involved in the regulation of crucial biological 
processes, including transcription, cell cycle progression, caloric-restriction responses, 
apoptosis, circadian rhythms, chromatin dynamics regulation, telomerase activity, 
intracellular calcium mobilization and metabolic pathways. All these events undergo 
changes during malignant transformation and cancer progression [15]. Therefore, NAD-
dependent metabolic and signaling pathways are altered in cancer cells leading to an 
increased NAD demand in these cells. The permanent NAD recycling is essential to fuel 
bioenergetic processes and maintain cell proliferation. NAD-dependent enzymes release 
nicotinamide during their reaction that needs to be recycled to maintain tissue NAD levels 
[16]. Most NAD in humans is resynthesized from nicotinamide [17]. The conversion of 
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nicotinamide to NAD is mediated by nicotinamide phosphoribosyltransferase (NAMPT), 
the rate-limiting enzyme in the mammalian NAD biosynthesis starting from nicotinamide 
[16, 18]. 
 
Figure 2. NAD - key regulator in cancer cell metabolism. The function of NAD as coenzyme 
is depicted in light blue, such as in glycolysis and the pentose phosphate pathway. NAD is also 
consumed by NAD-dependent enzymes shown in yellow, such as poly (ADP-ribose) polymerases 
(PARPs), mono-ADP ribosyltransferases (MARTs), sirtuins (SIRTs), ADP-ribosyl cyclases (CD38) 
with a concomitant release of nicotinamide (NAM) which has a negative feedback function. NAM 
enters the NAD salvage pathway (blue) and is recycled by nicotinamide phosphoribosyltransferase 
(NAMPT) to nicotinamide mononucleotide (NMN) and further to NAD by nicotinamide 
mononucleotide adenylyltransferases (NMNATs). The NAMPT inhibitor FK866 is depicted in 
orange. 
 
A detailed overview about the physiological and pathophysiological functions of 
NAMPT is given in Chapter 2. An inhibition of NAMPT activity represents one of the 
most powerful ways to lower organismal NAD levels. Alternative NAD precursors, such as 
nicotinic acid (NA), nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) 
can be administered to rescue the toxic effects of NAMPT inhibition [19]. This strategy 
could be used to increase the therapeutic potential of NAMPT inhibitors through the 
rescue of normal tissues. 
1.3 The NAD-dependent deacetylase SIRT1 and cancer 
Cancer cells possess a higher activity of NAD-dependent enzymes than non-transformed 
cells. NAD-dependent enzymes are involved in many crucial cellular pathways of cancer 
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cell progression [7]. For example, PARP1 is responsible for DNA repair and therefore 
necessary for DNA integrity [20]. Activation of PARP1 consumes large amounts of NAD 
[21] and a lot of research interest has been focused on PARP inhibition in cancer therapy 
[22]. 
Another important family of NAD-dependent enzymes are sirtuins, which belong 
to the class III of histone deacetylases (HDACs), also known as lysine deacetylases. Sirtuins 
can deacetylate not only histones, but also non-histone proteins at specific loci and thus 
directly link metabolic and bioenergetic homeostasis and gene regulation. Furthermore, 
NAD-dependent deacetylation regulates the activity, stability or localization of target 
proteins. First discovered as caloric restriction response proteins who extend life span in 
lower organisms, further studies revealed that sirtuins are involved in a multitude of 
biological processes, such as senescence, aging, DNA repair, survival, metabolism and 
proliferation. Some members of the various classes of histone deacetylases (HDACs) have 
been shown to be overexpressed in diverse cancers. Thus, resulting changes in the 
acetylation patterns on proteins may contribute to cellular transformation and tumor 
progression. Accumulating evidence has indicated that SIRT1, the most studied of the 
group of SIRTs, is a key regulator of life span extension, DNA damage, metabolism, stress, 
inflammation, and cancer development [23–28]. The non-histone deacetylation targets of 
SIRT1 include transcription factors, such as p53, Forkhead box ‘Other’ (FoxO) proteins, 
hypoxia-inducible factor 2α (HIF-2α), E2F1, hypermethylated in cancer 1 (HIC1), B-cell 
lymphoma 6 protein (BCL6), peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC1-α), peroxisome proliferator-activated receptor γ (PPARγ), 
nuclear factor κB (NF-κB) and others; as well as DNA repair proteins including Ku-70 and 
signaling factors such as endothelial nitric oxide synthase (eNOS) [27, 29]. 
SIRT1 has been described to act as tumor promotor as well as tumor suppressor 
[23, 27]. Influencing diverse physiological processes, it is not surprising that the role of 
SIRT1 in cellular growth control is complex and its enzymatic activity exerts important cell-
type specific effects [30, 31]. SIRT1 overexpression has been shown in different cancer 
types, such as hematopoietic malignancies like leukemia and several solid tumors of the 
breast, colon, prostate and liver [32–38]. Due to the fact that SIRT1 activity influences 
diverse physiological processes associated with cell growth and motility [26, 39, 40], its 
overexpression could have grave consequences for tumor progression. In contrast, SIRT1 
inhibition was shown to be effective in reducing cell proliferation, while inducing apoptosis 
in cancer cells [41–43]. The specific small-molecule inhibitor of SIRT1 catalytic activity, 
EX-527 increased p53 acetylation at lysine 382 but had no effect on viability of primary 
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human mammary epithelial cells [44]. However, tumor cells treated with EX527 showed 
increased cell cycle arrest [43]. Additionally, SIRT1 plays also an important role in DNA 
damage response processes which are crucial for maintaining genome stability when cells 
are exposed to genotoxic factors [28, 45].  
The first discovered non-histone target of SIRT1, p53, is suggested to play a central 
role in SIRT1-mediated functions in tumorigenesis and senescence [46, 47]. Normally, p53 
protein is not activated and thus maintained at a low level through the MDM2-mediated 
ubiquitination and degradation pathway. However, under cellular stress including genotoxic 
stress, p53 protein rapidly accumulates and activates downstream biological functions, 
including cell cycle arrest, DNA repair, and apoptosis [48, 49]. Mutations within the p53 
gene have been documented in more than half of all human tumor types [50]. Post-
translational modifications, such as phosphorylation, ubiquitination and acetylation regulate 
the amount, stability and activity of p53. The C-terminal region acetylation of p53 activates 
its sequence-specific DNA binding activity and target gene expression as well as increases 
its stability due to inhibition of ubiquitination at acetylated lysines [48]. SIRT1 deacetylates 
p53 at lysine residue 382 (K382) and thereby inhibits its transcriptional activity and 
apoptosis [47]. For example, SIRT1 knockout mice showed increased p53 acetylation and 
were more susceptible to radiation-induced apoptosis, raising the possibility that SIRT1 can 
facilitate tumor growth by antagonism of p53 [51] and inhibition of SIRT1 activity induces 
senescence-like cell growth arrest in human cancer cells [42, 43, 52].  
 
1.4 Targeting the NAMPT-mediated NAD salvage pathway may prove a 
cancers Achilles’ heel 
The uncontrolled proliferation presents a significant bioenergetic challenge to cancer cells 
as they must generate enough energy and acquire or synthesize biomolecules at a sufficient 
rate to meet the demands of proliferation. As mentioned above, targeting the NAD salvage 
pathway in cancer cells represents one of the most powerful tools to disturb the cancer cell 
energy metabolism and to modify NAD-dependent signaling pathways associated with 
DNA repair, proliferation, cell cycle and apoptosis.  
 
NAMPT inhibition 
Due to increased activity of NAD-dependent enzymes cancer cells rely on continuous 
supply of NAD from nicotinamide. Therefore, cancer cells often maintain intracellular 
NAD levels by overexpressing NAMPT, the key enzyme in the NAD-salvage pathway 
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starting from nicotinamide. NAMPT overexpression has been shown in different cancer 
types, including colorectal, ovarian, breast, gastric, prostrate, well-differentiated thyroid, 
and endometrial carcinomas, and myeloma, melanoma, and astrocytomas [53]. However, 
there are currently no studies available about the expression and regulation of NAMPT in 
hepatocellular carcinoma (HCC). HCC belongs to the second leading cause of cancer-
related deaths [54]. The only available proven systemic therapy for HCC is the multi-target 
kinase inhibitor sorafenib. An effective second-line agent for those with sorafenib failure or 
intolerance has yet to be identified [55]. Thus, there is an ongoing search for molecular 
pathways and novel compounds as potential treatment option for HCC.  
Clinical studies reported increased serum NAMPT levels in cancer patients with a 
positive correlation between either tissues or circulating levels and stage progression. In 
vitro studies could show that cell lines overexpressing NAMPT were significantly more 
resistant to chemotherapeutic agents than control cells. In contrast, stable NAMPT knock-
down cells were shown to be more sensitive to methylmethane sulfonate (MMS), a DNA 
alkylating agent [56]. Additionally, NAMPT was shown to activate the mitogen-activated 
protein kinases (MAPK)-dependent pathway and to stimulate the vascular endothelial 
growth (VEGF) factor promoting angiogenesis, a crucial process during tumor growth and 
expansion [57, 58]. Targeting NAMPT activity represents a novel therapeutic strategy for 
HCC. 
The specific NAMPT inhibitor FK866 (also known as APO866 or WK175) is a 
competitive inhibitor and has no inhibitory effect on nicotinic acid 
phosphoribosyltransferase (NAPRT) or nicotinamide mononucleotide adenylyltransferase 
(NMNAT) [59–61]. Crystal structure analysis revealed that FK866 is bound in a tunnel at 
the interface of the NAMPT dimer, and mutations in this binding site can abolish the 
inhibition by FK866. Thus, FK866 competes with nicotinamide at the active binding site of 
NAMPT. Given that NAMPT is the sole enzyme that recycles nicotinamide to NAD, 
NAMPT inhibition not only affects NAD levels but may also influence nicotinamide levels. 
Nicotinamide, which non-competitively inhibits sirtuins without affecting their binding of 
NAD, has been widely used as a pan-sirtuin inhibitor [62, 63]. FK866-mediated NAMPT 
inhibition causes a delayed cell death by ATP depletion [59, 64]. The mechanism of cancer 
cell death is suggested to be apoptosis, depending on cellular ATP levels [59, 65, 66]. 
However, autophagy has been also reported [67]. In recent years, FK866 has been 
evaluated in a broad variety of tumors, including solid tumor-derived cells and leukemia 
cells in vitro [68, 69] and in nude mouse xenografts, where FK866 was able to reduce or 
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attenuate tumor growth [69, 70]. In healthy cells, FK866 showed low cytotoxicity due to 
their comparatively slow metabolic rate. 
Currently, FK866 is undergoing phase II clinical trials for advanced melanoma and 
cutaneous T-cell lymphoma (ClinicalTrials.gov Identifier: NCT00431912), for phase I/II 
for refractory B-cell Chronic Lymphocytic Leukemia (ClinicalTrials.gov Identifier: 
NCT00435084) as well as advanced cutaneous melanoma (ClinicalTrials.gov Identifier: 
NCT00432107). In pre-clinical studies thrombocytopenia was the dose limiting toxicity and 
no other hematologic toxicities were noted other than mild lymphopenia and anemia [61]. 
 
Resveratrol and cancer 
Increasing research efforts have been made to investigate the use of natural agents, alone or 
in combination with established anti-cancer agents for cancer therapy. During the past 
decade, significant work has been done towards identifying the health-beneficial effects of 
the antioxidant resveratrol in a variety of bioassay- and disease- models. The polyphenol 
resveratrol (3,5,4′-trihydroxystilbene) is a naturally occurring phytoalexin found in grapes, 
berries and peanuts. It is synthesized as a plant antibiotic to counteract pathogen infections, 
including fungal infection or UV radiation and in response to environmental and mechanic 
stress [71, 72]. 
Since studies have shown that resveratrol is able to partially mimic the effects of a 
calorie restriction [73, 74] which is known to extend lifespan in diverse species and increase 
NAMPT and SIRT1 expression, further studies identified resveratrol as potential natural 
SIRT1 activator [75]. Whether or not SIRT1 is directly activated by resveratrol has been the 
subject of a contentious debate [75–77]. Recent studies reported that resveratrol action 
only triggers SIRT1-mediated deacetylation in a substrate-specific fashion, and even led to 
a paradoxical inhibition of SIRT1 actions on certain substrates. Many contradicting studies 
called resveratrol as a SIRT1 activator into question. The assay that initially identified 
resveratrol as a SIRT1 activator has used the non-physiological “Fluor de Lys” substrate 
for screening which can lead to artefactual results. Thus, resveratrol failed to activate 
SIRT1 with native peptides or full-length protein substrates, whereas resveratrol does 
activate SIRT1 when using fluorophore-containing peptides [76–79]. There are also 
controversies between the in vivo effects of resveratrol treatment and SIRT1 genetic gain-
of-function models [80]. Altogether, these data indicate that resveratrol can no longer be 
seen as global SIRT1 activator. Further, one has to take into account that there is 
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uncertainty whether resveratrol itself or one of its metabolized forms accounts for the 
biological effects. 
Recent studies revealed that resveratrol activates the AMP-activated kinase 
(AMPK) whereas the underlying mechanism of activation is still unclear. One explanation 
could be the decrease of ATP levels and concomitant increase in AMP/ATP or ADP/ATP 
ratios induced by high concentrations of resveratrol (100-300µM) [81]. Low concentration 
of resveratrol (< 50µM) can also increase AMPK activation without decreasing energy 
equivalents [82, 83] but by inhibition of phosphodiesterases (PDE) that leads to increased 
cAMP levels [84] or SIRT1 activation [85]. Moderate dose of resveratrol has been shown to 
require SIRT1 activity to activate AMPK and to exert beneficial effects on mitochondrial 
function while high dose of resveratrol activated AMPK in a SIRT1-independent manner, 
demonstrating that resveratrol dosage is a critical factor. 
Many preclinical and clinical studies have shown that resveratrol can prevent or 
slow the progression of a wide variety of age-associated diseases, including cancer, diabetes, 
arthritis, and coronary, neurodegenerative, and pulmonary diseases [86]. Resveratrol was 
shown to inhibit carcinogenesis at all three stages (initiation, promotion, and progression). 
The same study demonstrated that topical application of resveratrol reduced the number of 
skin tumors in a mouse melanoma model by up to 98% [87]. Systemic administration of 
resveratrol has since been shown to inhibit the initiation and growth of tumors in a wide 
variety of rodent cancer models [86]. Several in vitro studies reported that resveratrol exerts 
its multiple anti-cancer effects by inducing cell cycle arrest and apoptosis [88–90]. For 
example, resveratrol prevents the expression of the tumor-derived nitric oxide synthase to 
block tumor growth and migration and is also acting as an antioxidant to prevent DNA 
damage that can lead to tumor formation [88, 89, 91]. However, on the other hand recent 
studies also revealed that resveratrol induces DNA damage in colorectal cancer as well as in 
head and neck squamous carcinoma [92, 93] which puts the antioxidant properties of 
resveratrol into question. In addition, the activity of cyclooxygenases (COX) which are 
known to play a role in tumorigenesis by promoting tumor cell proliferation, are also 
inhibited by resveratrol [94, 95]. 
In recent years, numerous studies further revealed that resveratrol decreases the 
DNA binding activity of the NF-κB, a transcription factor that is known to be upregulated 
in cancers and induces the transcription of genes that promote tumor growth [96–98]. 
Likewise, several reports demonstrated the chemopreventive and chemotherapeutic 
potential of resveratrol in HCC. For example, it was found that resveratrol prevents 
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diethylnitrosamine (DENA)-initiated hepatocarcinogenesis in rats through suppression of 
inflammation and oxidative stress [99]. The effects of resveratrol on NAMPT and SIRT1 in 
hepatocarcinoma cells have yet to be investigated. Elucidating how resveratrol exerts its 
effects would provide not only new insights in its fundamental biological actions but also 
open new avenues for the design and development of more potent drugs for HCC therapy. 
 
1.5 Metabolic Checkpoints: AMPK and mTOR 
AMPK 
The AMPK is a highly conserved heterotrimeric serine/threonine kinase and occupies a 
central role in linking metabolism and cancer development [100, 101]. Its pharmacological 
activation by metformin was used for the treatment of metabolic syndrome and type 2 
diabetes. During the last decades, there is emerging evidence showing that AMPK is 
implicated in cancer cell growth and metabolism [100-102]. Likewise, under conditions of 
metabolic stress, typically by an increase in the cellular AMP/ATP ratio under conditions 
such as glucose deprivation, hypoxia, ischemia, and heat shock, AMPK is activated [103–
105]. One of the newly uncovered links directly connecting cell metabolism and cancer 
came from the discovery that the serine/threonine kinase LKB1 (liver kinase B1; also 
known as serine/threonine kinase 11 - STK11), a known tumor suppressor, was the key 
upstream activator of AMPK [106, 107]. Once activated it regulates various processes, 
including development, cell cycle progression, apoptosis, and autophagy [108]. Inactivation 
of AMPK has been implicated in cancer development and malignant behaviors in several 
cancers, including prostate, lung, and breast. Loss of AMPKα increased HIF-1α expression, 
thereby promoting the Warburg effect by increasing aerobic glycolysis and lactate 
production [101]. A very recent paper showed that AMPK was less activated in the 
majority of the patients with HCC and discussed that it may serve as a valuable predicting 
factor for recurrence and poor survival. Moreover, activation of AMPK by metformin 
inhibited NF-κB and signal transducer and activator of transcription 3 (STAT3)-signaling 
activity, and thus inhibited HCC growth [109]. On the contrary, another study reported 
that AMPK promotes hepatocarcinogenesis by destabilizing p53 in a SIRT1-dependent 
manner [110]. Thus, modulation of AMPK has emerged as an important target for the 
treatment of obesity, diabetes, and cancer. 
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mTOR 
Under energy starvation condition it was shown that AMPK phosphorylates tuberous 
sclerosis complex 2 (TSC2) to inhibit mammalian target of rapamycin (mTOR) signaling 
[111]. This observation revealed a direct connection of AMPK with mTOR and cancer. 
mTOR is a highly conserved serine/threonine kinase involved in regulating major cellular 
functions including growth and proliferation. mTOR functions as the catalytic subunit of 
two distinct protein kinase complexes, designated as mTOR complex 1 (mTORC1) and 
mTOR complex 2 (mTORC2), respectively [112]. Deregulation of the mTOR signaling 
pathway is one of the most commonly observed pathological alterations in human cancers. 
Components of this complex are often overexpressed in a large number of cancers and 
promote malignant transformation in experimental systems [113]. 
Specifically, mTORC1 is regulated by sensing intracellular as well as extracellular 
stimuli, such as stress, nutrients, energy, oxygen levels and growth factors. Once activated 
mTORC1 regulates protein translation and cell metabolism through directly 
phosphorylating the eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) 
and p70 ribosomal S6 kinase (p70S6K). It also activates sterol regulatory element-binding 
protein (SREBP) and autophagy components to promote protein and lipid synthesis, 
lysosome biogenesis, energy metabolism and to inhibit autophagy [113]. In contrast, 
mTORC2 is less sensitive to nutrients but more sensitive to growth factors. Studies on 
AMPKα-deficient tumors demonstrated an increased activation of the mTORC1 targets 
p70S6K and 4E-BP1 suggesting that AMPK and mTOR serve as a signaling nexus for 
regulating cellular metabolism, energy homeostasis and cell growth. Thus, a dysregulation 
of each pathway may contribute to cancer development. In recent years, many studies 
revealed a link between the NAMPT-mediated NAD metabolism and regulation of mTOR 
signaling. Recent studies showed that p70S6K is regulated by sirtuins-mediated acetylation 
that influences the mTORC1-dependent p70S6K activation [114] and NAMPT 
overexpression reduces mTOR activation [115].  
 
1.6 Aims of this thesis 
As mentioned above, cancer cell metabolism is characterized by fundamental changes in 
pathways of energy metabolism. These metabolic alterations require increased amounts of 
NAD. Thus, cancer cells have an increased NAD turnover and elevated activity of NAD-
dependent enzymes, such as sirtuins. The chemopreventive and chemotherapeutic potential 
of the SIRT1 modulator resveratrol was shown in animal models of HCC. The 
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AMPK/mTOR signaling network is connected to and influenced by sirtuins and the 
NAD/NADH ratio and was also shown to be involved in hepatocarcinogenesis. 
Based on these facts, I hypothesised that targeting NAMPT activity by 
pharmacological inhibition reduces cell viability of hepatocarcinoma cells. Thus, the aims 
of my presented work were (1) to investigate the chemotherapeutic potential and molecular 
mechanisms of the specific NAMPT inhibitor FK866 and the phytochemical resveratrol on 
hepatocarcinoma cells and to find out whether there are differences compared to non-
cancerous primary human hepatocytes; (2) to investigate whether NAMPT inhibition by 
FK866 would induce changes in the energy metabolism and the AMPK/mTOR signaling 
that would lead to a reduction of cancer cell proliferation and (3) to address the relevance 
of NAMPT and SIRT1 in resveratrol´s mode of action as well as the underlying 
mechanism of resveratrol induced cell death in hepatocarcinoma cells.  
Figure 3. Hypothesis and aims of this thesis. I proposed the following hypothesis: Targeting 
NAMPT activity by pharmacological inhibition reduces cell viability of hepatocarcinoma cells. To 
verify my hypothesis I aimed to investigate the chemotherapeutic effects of the NAMPT inhibitor 
FK866 and the phytochemical resveratrol. I intended to find out whether a FK866-mediated 
NAMPT inhibition would induce energy stress in hepatocarcinoma cells that would lead to 
activation of AMP-activated kinase (AMPK) and downregulation of mammalian target of 
rapamycin (mTOR) complex1 (mTORC1)-signaling. If NAD depletion would activate AMPK, 
FK866 would be identified as novel AMPK activator in hepatocarcinoma cells. I also aimed to 
analyse the different sensitivities of hepatocarcinoma cells and non-cancerous hepatocytes to 
NAMPT inhibition. Reduced NAD levels would negatively influence SIRT1 deacetylase activity 
which was described to increase p53 acetylation at lysine residue 382 and to induce cell cycle arrest 
via induction of p21. Because resveratrol has been described as natural SIRT1 modulator, I aimed 
to investigate the relevance of NAMPT and SIRT1 in resveratrol´s mode of action and 
chemotherapeutic function. I assumed that resveratrol does not act as a SIRT1 activator in cancer 
cells. Thus, it should be addressed whether NAMPT and SIRT1 are involved in resveratrol-
mediated effects on cell cycle arrest or apoptosis.  
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Therefore, I used different models of human hepatocarcinoma cells and performed 
a comprehensive study covering aspects in the field of cellular responses, enzyme functions 
and signaling pathways. As control, non-cancerous primary human hepatocytes were used. 
These investigations provide new insights into the role of the NAMPT-mediated NAD 
salvage pathway in energy metabolism of hepatocarcinoma cells and contribute to a better 
understanding of the molecular mechanisms and chemotherapeutic function of FK866 and 
resveratrol and will help to identify new therapeutic strategies for HCC cancer therapy. 
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Nicotinamide phosphoribosyltransferase (NAMPT) is a regulator of the intracellular NAD 
(nicotinamide adenine dinucleotide) pool. NAD is an essential coenzyme involved in cellular redox 
reactions and a substrate for NAD-dependent enzymes. NAD concentrations are decreased in 
various metabolic disorders and during aging. Through its NAD-biosynthetic activity, NAMPT was 
shown to influence the activity of NAD-dependent enzymes, thereby regulating cellular 
metabolism. Besides its intracellular enzymatic function, NAMPT is also found in circulation and 
has cytokine-like activity. Extracellular NAMPT levels were shown to be associated with various 
metabolic disorders. NAMPT is able to modulate important processes in the pathogenesis of 
obesity and related disorders like non-alcoholic fatty liver disease and type 2 diabetes by regulating 
the oxidative stress response, apoptosis, lipid and glucose metabolism, inflammation and insulin 
resistance. NAMPT also plays a crucial role in cancer cell metabolism, is often overexpressed in 
tumor tissues and an experimental target for anti-tumor therapies. We will discuss the current 
understanding of NAMPT functions with an emphasis on recent progress on NAMPT’s 
physiological role and its relevance in various human diseases and conditions, such as obesity, non-
alcoholic fatty liver disease, type 2 diabetes, aging and cancer. 
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2.1 Introduction: NAD metabolism, NAMPT and mechanism of action 
Nicotinamide phosphoribosyltransferase (NAMPT) was originally discovered as a cytokine 
named Pre-B-cell colony enhancing factor (PBEF) [1] acting as a co-factor for B-cell 
maturation. The bacterial and murine homologs of NAMPT were later identified as 
enzymes involved in NAD biosynthesis [2, 3]. Additionally, NAMPT was described to be 
highly expressed in visceral compared to subcutaneous adipose tissue and its plasma levels 
correlated with obesity outcome. Therefore, NAMPT was recognized as an adipokine and 
renamed visfatin [4]. NAMPT/visfatin was described to directly bind to and activate the 
insulin receptor at a binding site distinct from insulin. However, due to controversies about 
the results, this paper was retracted [5]. While all three names (NAMPT, PBEF, visfatin) 
have been used, “NAMPT” has been approved as the official nomenclature of the protein 
and the gene by both the HUGO Gene Nomenclature Committee and the Mouse 
Genomic Nomenclature Committee [6]. NAMPT will therefore be used throughout this 
review. We will discuss the current understanding of NAMPT functions with an emphasis 
on recent progress on NAMPT’s physiological role and its relevance in various human 
diseases and conditions, such as obesity, non-alcoholicfatty liver disease, type 2 diabetes, 
aging and cancer. 
 
NAD biosynthesis and NAMPT enzyme activity  
NAD (nicotinamide adenine dinucleotide) is an essential coenzyme involved in cellular 
redox reactions and a substrate for NAD-dependent enzymes. In mammals, NAD can be 
synthesized either from tryptophan or from vitamin B3, which includes nicotinamide, 
nicotinic acid and nicotinamide riboside. The de novo pathway using L-tryptophan mainly 
occurs in the liver, but it is assumed that the main source of NAD is produced by salvage 
pathways using vitamin B3 [7]. That includes the NAD precursors nicotinamide (NAM), 
nicotinic acid (NA) and nicotinamide riboside (NR). Nicotinamide rather than nicotinic 
acid is thought to be the predominant NAD precursor in mammals [8–10]. Nicotinamide is 
also a product of deacetylation and ADP-ribosylation reactions catalysed by NAD-
dependent enzymes [11–13]. NAMPT produces NMN (nicotinamide mononucleotide) 
from nicotinamide and PRPP (5′-phosphoribosyl-1-pyrophosphate), catalysing the rate-
limiting step in the mammalian NAD salvage pathway from nicotinamide [3, 14]. NMN, 
together with ATP, is then converted into NAD by nicotinamide/nicotinic acid 
mononucleotide adenylyltransferase (NMNAT). NR is converted into NMN by 
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nicotinamide riboside kinase (NRK) [15], entering the NAD salvage pathway. A simplified 
overview of mammalian NAD metabolism is depicted in figure 1.  
Figure 1. Overview of the mammalian NAD metabolism. The NAD de novo kynurenine 
pathway is comprised of several steps. The first rate-limiting step is catalysed by tryptophan-2,3,-
dioxigenase (TDO) or indoleamine-2,3,-dioxigenase (IDO). By multiple reactions, L-tryptophan is 
converted to nicotinic acid mononucleotide (NAAM). At this stage, nicotinic acid (NA) enters the 
pathway and is phosphoribosylated by nicotinic acid phosphoribosyltransferase (NAPRT). NAAM 
is then converted to nicotinic acid adenine dinucleotide (NAAD) by nicotinamide/nicotinic acid 
mononucleotide adenylyltransferase enzymes 1-3 (NMNAT1-3). Finally, NAAD is amidated by 
NAD synthase (NADS) to yield NAD. Nicotinamide (NAM) is another NAD precursor and a 
product of deacetylation and ADP-ribosylation reactions catalysed by NAD-dependent enzymes 
such as sirtuins (SIRTs), poly (ADP-ribosyl) transferases (PARPs), mono (ADP-ribosyl) 
transferases (MARTs) and ADP-ribosyl cyclases like CD38. Nicotinamide 
phosphoribosyltransferase (NAMPT) produces nicotinamide mononucleotide (NMN) from 
nicotinamide and 5′-phosphoribosyl-1-pyrophosphate (PRPP), catalysing the rate-limiting step in 
the NAD salvage pathway from nicotinamide. NMN is then converted into NAD by NMNAT1-3. 
Nicotinamide riboside (NR) enters the NAD biosynthesis pathway by phosphorylation to NMN 
catalysed by nicotinamide riboside kinase (NRK).  
 
NAMPT occurs intracellular, mainly located in the cytoplasm and nucleus, but is 
also found in mitochondria [16], and in circulation [17]. Significant NAMPT sequence 
homology exists among prokaryotic organisms, primitive metazoans such as marine 
sponges, and humans [2], suggesting a crucial role for NAMPT in cellular metabolism and 
survival. Several groups have characterized the structural and enzymological features of 
mammalian NAMPT [18–25]. Structural and mutagenesis studies have shown that mutants 
with impaired dimerization exhibit attenuated enzymatic activity [20] and that Asp219 is 
important in defining the substrate specificity of NAMPT [23], which does not convert 
nicotinic acid [14, 26]. NAMPT can autophosphorylate at H247 [18, 20] which increases its 
affinity for nicotinamide and its enzymatic activity up to 1000-fold [18]. To our knowledge, 
no other regulatory post-translational modification has been described so far. However, 
this does not preclude a role for phosphorylation, ubiquitinylation and acetylation in the 
regulation of NAMPT function.  
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NAMPT single nucleotide polymorphisms (SNPs) and regulation of NAMPT 
expression and activity 
From analysing tissue sources of 719 cDNA clones, it was found that NAMPT is expressed 
in nearly all organs, tissues, and cells examined [1, 27]. This ubiquitous distribution of 
NAMPT suggests pleiotropic functions of this protein in human physiology. A number of 
single nucleotide polymorphisms (SNPs) have been detected and are associated with a 
number of disease phenotypes (e.g. acute respiratory distress syndrome [28], coronary 
artery disease [29], obesity [30], acute lung injury [31, 32], sepsis [33], bladder cancer [34], 
glucose and lipid parameters [35]). However, several studies found that genetic variations in 
the NAMPT gene do not play a major role in the development of obesity or type 2 
diabetes[36–38]. The relevance for genetic variations of NAMPT in disease development 
may depend on whether the active site, the assembly of the active dimer form or gene 
expression is affected. A recent study showed that rs2302559 significantly correlates with 
NAMPT serum levels [39]. Therefore, functional association studies of NAMPT variants 
and their secretion patterns are yet to be performed.  
Interestingly, previous studies could show that the NAMPT gene is regulated by the 
core clock machinery. Intracellular NAD levels cycle within a 24-hour rhythm. CLOCK: 
BMAL1 regulates the circadian expression of NAMPT. Sirtuin1 (SIRT1) is recruited to the 
NAMPT promoter and contributes to the circadian synthesis of NAMPT [40, 41]. Since 
obesity influences the expression of circadian regulatory genes like Clock, Rev-Erb-α and 
Bmal [42], changes in NAMPT expression and function might contribute to the 
development of obesity-related co-morbidities. Furthermore, hepatic forkhead box protein 
(FoxO) transcription factors regulate NAMPT gene expression and the hepatic triglyceride 
homeostasis. For instance, NAMPT overexpression reduced, whereas its knockdown 
increased hepatic triglyceride levels in vitro and in vivo [43]. Studies on human NAMPT in 
skeletal muscle reported that glucose restriction and exercise increased NAMPT expression 
and that mitochondria content correlated with NAMPT levels [44]. Furthermore, different 
studies implicated that NAMPT gene expression was elevated after stimulation with TNFα 
[45], IL-6 [46] and under hypoxic conditions [47, 48]. This could be a reason for the 
increased level of NAMPT mRNA in states of obesity and insulin resistance and 
inflammation. However, contradicting data showed that IL-6 down regulated NAMPT 
synthesis in adipocytes [49]. Recently, we could demonstrate that stimulation with the plant 
derived polyphenol resveratrol led to increased NAMPT mRNA expression, activity as well 
as NAD levels in human hepatocytes, although NAMPT protein levels were unchanged. 
Metabolic factors influencing NAMPT expression are summarised in table 1. 
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Table 1. Metabolic factors influencing NAMPT expression. 
Factor Action 
glucose restriction ↑in skeletal muscle [44] 
↑in hepatocytes [100] 
↑in human preadipocytes and adipocytes [91] 
glucose ↑in human adipocytes [87] 
fructose ↑in brown and white adipose tissue of fructose-rich-diet 
fed mice [112] 
↓in circulation of fructose-rich-diet fed mice [112] 
oxidized low density lipoprotein ↑in 3T3-L1 adipocytes [89] 
growth hormone ↓in 3T3-L1 adipocytes [90] 
 interleukin-6 ↑in rheumatoid arthritis [46] 
↓in 3T3-L1 adipocytes [90] 
Tumor necrosis factor alpha ↑in adipose tissue [45] 
↓in 3T3-L1 adipocytes [90] 
palmitate ↑in HepG2 cells [103] 
leucine ↑in high-fat-diet fed mice [102] 
dexamethasone ↑in human preadipocytes and adipocytes [91] 
↑in 3T3-L1 adipocytes [90] 
isoproterenol ↑in human preadipocytes [91] 
↓in 3T3-L1 adipocytes [90] 
exercise ↑in skeletal muscle [44] 
hypoxia ↑in 3T3-L1 adipocytes [48] 
↑in MCF-7 breast cancer cells [47] 
↑up and ↓down regulation of NAMPT expression 
 
NAD-dependent enzymes 
NAMPT is a regulator of the intracellular NAD pool [3, 14]. Through its NAD-
biosynthetic activity, NAMPT was shown to influence the activity of NAD-dependent 
enzymes, such as sirtuins [14, 50, 16, 51–53] and poly (ADP-ribose) polymerase (PARP)-1 
[54], thereby regulating cellular metabolism, mitochondrial biogenesis [55–57] and adaptive 
stress responses, including inflammatory, oxidative, proteotoxic, and genotoxic stresses 
[58]. Several comprehensive reviews about the roles of NAD-dependent enzymes in 
cellular metabolism have been published recently [59–62]. Mono-ADP-ribosyl transferases 
and ADP- ribosyl cyclases [63] are involved in several physiological processes, including 
calcium signaling and DNA repair. Since these enzymes also use NAD as substrate and are 
also inhibited by their product nicotinamide, it is likely that NAMPT action influences their 
activity.  
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NAMPT in circulation 
Several studies indicate that circulating or extracellular NAMPT (eNAMPT) may function 
as a growth factor [1, 64–68]. However, the mechanism of NAMPT secretion and its 
physiological function in extracellular space is far from clear as well as whether NAMPT 
occurs in the same form and configuration in the cell and in circulation. NAMPT in human 
serum was described to be secreted from adipocytes [17, 69]. During the last years, many 
other cell types have been identified to release NAMPT, such as hepatocytes [70, 71], 
leukocytes [27], cardiomyocytes [72], neurons [73, 74], amniotic epithelial cells [75] and 
LPS-activated monocytes [76, 77]. Whether circulating NAMPT is enzymatically active in 
vivo or not is still a matter of debate due to the low concentration of PRPP and ATP in 
extracellular space [78]. However, it raises the question whether enzymatic activity of 
circulating NAMPT is linked to pathophysiological conditions where plasma PRPP and 
ATP levels may increase due to cell death. Since a receptor for eNAMPT has not been 
discovered yet, the mechanism of NAMPT signal transduction continues to be subject of 
scientific research as it is of major importance in targeting circulating NAMPT in various 
pathological conditions. Whether circulating NAMPT exhibits pro- or anti-inflammatory 
activity is still being debated [17, 72–74, 79, 80]. However, several studies have shown pro-
inflammatory effects of eNAMPT on different cell types which involve iNOS induction 
[81], ERK1/2 activation [65], NF-κB activation [33, 81] and cytokine production, such as 
TNFα, IL-6, IL-1β [33] and TGF-β [82]. Figure 2 gives an overview on NAMPT 
physiological actions. It appears that inflammatory cytokine production and NAMPT gene 
expression are regulated by a positive feedback activation loop and that NAMPT acts as a 
stress-response protein. This implicates an interesting connection between chronic 
inflammation and NAMPT-mediated NAD biosynthesis. A better understanding of its 
mechanisms of action is a prerequisite for the use of NAMPT-related pathways as a 
therapeutic option in relevant diseases. 
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Figure 2. Overview on physiological actions of NAMPT. Intracellular NAMPT (iNAMPT) has 
been found in the cytoplasm, nucleus and mitochondria. NAMPT exerts its effects by maintaining 
intracellular NAD levels and recycling nicotinamide produced by the action of NAD-dependent 
enzymes like sirtuins (SIRTs)-1,-6,-7 and poly-(ADP-ribose) polymerase (PARP)-1 in the nucleus, 
SIRT-1,-2 in the cytoplasm and SIRT-3,-4,-5 in the mitochondria. The ectoenzyme CD38 produces 
cADPR (cyclic ADP-ribose) and regulating intracellular Ca2+ signaling. NAMPT expression is 
induced by the circadian regulators CLOCK and BMAL in complex with SIRT1. Other stimulators 
of NAMPT expression include mechanical stress and pro-inflammatory cytokines (TNFα, IL-1β, 
IFNγ). NAMPT is secreted from different cell types and most likely released from dying cells 
together with ATP and 5′-phosphoribosyl-1-pyrophosphate (PRPP). Therefore, a potential 
extracellular production of nicotinamide mononucleotide (NMN) would take place that 
subsequently may enter the cell, possibly after being converted into nicotinamide riboside (NR). 
Apart from enzymatic activity, extracellular NAMPT (eNAMPT) was shown to act as a pro- or 
anti-inflammatory cytokine on multiple signaling pathways, such as extracellular signal regulated 
kinase (ERK)1/2, IL-6/Signal transducer and activator of transcription (STAT)3, 
phosphoinositide-3-kinase (PI3K)/AKT, p38 mitogen activated protein kinase (MAPK) and 
nuclear factor-κB (NF-κB), influencing the expression of several cytokines (TNF-α, IL-1β, TGFβ). 
An eNAMPT receptor is not yet identified.  
 
2.2 NAMPT in Obesity and non-alcoholic fatty liver disease (NAFLD) 
NAMPT and white adipose tissue in obesity 
White adipose tissue (WAT) is a key regulator in the development of obesity and obesity-
related disorders by operating as a fat storage organ and releasing fatty acids and adipokines 
[83] into the circulation. Thus, WAT acts as a functional endocrine unit [84]. Ever since 
NAMPT was described as adipocytokine with insulin-mimetic effects [4], the discussion 
about the role of NAMPT in obesity and obesity-related disorders has been continued. 
Different adipocyte models were shown to release NAMPT into the supernatant via a non-
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classical pathway [17, 69, 85], identifying adipose tissue as a source of circulating NAMPT. 
A meta-analysis including human studies on the association of NAMPT with obesity 
parameters found that circulating NAMPT levels were generally increased in subjects with 
obesity [86]. Human studies on the association of NAMPT with parameters of obesity 
published during the last five years are summarised in table 2.  
 
Table 2: Obesity and NAFLD. 
NAMPT in human studies NAMPT correlates with  
↑ Seruma and liverb in obese 
women (n=95) compared to 
normal weight women (n=38) 
↑ Seruma and liverb in obese 
women with NAFLD compared 
to obese women without 
NAFLD 
aIL-6 (r=0.496; p<0.001) 
aCRP levels (r=0.241; p=0.049)  
bresistin (r=0.436, p=0.018) 
bTNFα (r=0.328, p=0.028) [148]  
± Serum in subjects with 
NAFLD (n=114) compared to 
healthy non-diabetic controls 
(n=60)  
TNFα (r = -0.236, p = 0.011) [149] 
↓ Serum after 6 weeks weight 
reduction (n=35) 
No correlation [150] 
± Serum in obese healthy 
women (n=43) compared to 
normal weight women (n=43) 
carbohydrate intake (p=0.018, r=0.257) [151] 
↑ Serum in obese children 
(n=44) compared to normal 
weight children (n=50) 
BMI(r=0.247, p=0.029) (boys)  
IL-6 (r=0.427, p=0.013) (boys) [152] 
± Serum in higher-adiposity 
children and adolescents (n=67) 
(BMI=23.5 ±2.8 kg/m) 
compared to lower-adiposity 
group (BMI BMI=17.6±2.2 
kg/m) (n=68) 
abdominal fat, visceral fat, subcutaneous abdominal fat, 
plasma triglyceride level and HOMA-IR (lower-adiposity 
group) 
IL-6 (higher-adiposity group) [153] 
 
↑ Serum in obese children and 
adolescents (n=30) compared to 
normal weight children and 
adolescents (n=60) 
No correlation [154] 
↑ Serum in subjects with 
NAFLD (n=30) compared to 
controls without NAFLD 
(n=27) 
No correlation [155] 
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↑ Serum in morbidly obese 
women (n=93) compared to 
lean women (n=40)a 
↓ Serum 12 months after 
bariatric surgeryb  
↑ Subcutaneous and visceral 
adipose tissuec in morbidly 
obese women compared to lean 
women  
aIL-6 (r = 0.474, P < 0·001)  
aCRP (r = 0.239, P = 0.042) 
bTNFα (r = 0.434, P = 0.009) 
bIL-6 (r = 0.458, P = 0·006) 
cTNFα (r = 0.314, P = 0.075) 
cIL-6 (6 r = 0.747, P < 0.001) [156] 
↑ Serum in exogenous obese 
pubertal adolescents (n=40) 
compared to healthy adolescents 
(n=20) 
body weight (r=0.4, p=0.001),  BMI (r=0.5, p=0.001), waist-
to-hip ratio (r=0.5, =0.001) 
Serum triglycerides (r=0.3, p<0.05), LDL-C levels (r=0.3, 
p<0.05) 
Insulin (r=0.45, p=0.001), C-peptide (r=0.4, p<0.001), 
HOMA-IR (=0.4, p=0.01), glucose/insulin ratio (-r=0.4, 
p=0.002) [157]  
↑ Seruma and human peripheral 
blood cellsb in obese subjects 
compared to lean subjects 
aBMI (r=0.31; P=0.044), WHR (r=0.47; P=0.012)a  
bBMI (r=0.50; P=0.009), body fat percentage (r=0.48; 
P=0.014), waist-to-hip ratio (r=0.43; P=0.032)b  
aALT (r=0.41, P= 0.013), AST(r= 0.41, P= 0.014), γ-GT 
(r=0.41, P= 0.014)a 
bHIF1-α mRNA (r=0.45; P=0.030) [158] 
↑ Serum in obese children 
(n=14) compared to lean 
children (n=15)  
leucocyte counts (r=0.46, p<0.001) [27] 
↑ Serum in adult obese subjects 
(n=46) compared to control 
group (n=44) 
BMI (P<0.05), waist circumference, (P<0.001), hip 
circumference (P<0.001), HOMA (P<0.05) [159]  
↑ Serum in obese children and 
adolescents (n=88) compared to 
lean children and adolescents 
(n=22)  
waist circumference (r = 0.36, P = 0.036), BMI% (r = 0.38, P 
= 0.025) (boys) 
whole body insulin sensitivity index (r = -0.36, P = 0.036) 
(boys) 
IL-6 (r = 0.38, P = 0.024), thiobarbituric acid reactive 
substances (r = 0.52, P = 0.001) (boys) [160] 
↑ Serum in prepubertal obese 
children compared (n=100) to 
control children (n=42) 
Resistin, IL-6 [161] 
↓ Serum and liver in subjects 
with NAFLD (n=58) compared 
to healthy controls (n=27) 
No correlation [100]  
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↓ Visceral adipose tissue in 
subjects with NAFLD (n=77) 
compared to subjects without 
NAFLD (n=38) 
No correlation [162] 
↑ Liver in subjects with fibrosis 
(n=33) compared to non-
fibrosis subjects with NAFLD 
(n=7)  
fibrosis stage (r = 0.52, p = 0.03) [163]  
± Serum in obese women 
compared to lean women 
No correlation [164]  
↑ Serum in obese subjects 
(n=68) compared to healthy 
non-obese subjects (n=30) 
age (r = -0.26, p = 0.034), waist-to-hip ratio (r = -0.28, p = 
0.031) 
HbA(1c) (r = -0.36, p = 0.0037) [165] 
↓ Subcutaneous tissue in obese 
subjects (n=31) compared to 
control subjects (n=31) 
No correlation [166]  
↑up and ↓down regulation of NAMPT; ± no change 
 
Several metabolic factors found to be increased in obese subjects were also shown 
to influence NAMPT expression and/or release. Both glucose and oxidized low density 
lipoprotein was shown to stimulate NAMPT expression and release in human adipocytes 
via the PI3-kinase/AKT pathway [87–89]. In addition, glucose administration in human 
subjects led to increased eNAMPT levels [27]. Further in vitro studies showed that NAMPT 
mRNA expression increased during adipogenesis [90] and was stimulated by insulin 
resistance-inducing factors like IL-6, dexamethasone, growth hormone, TNFα and 
isoproterenol [49, 91]. The macrophage population in obese human visceral WAT was 
identified as another source of eNAMPT [92]. On the other hand, eNAMPT was found to 
induce an up-regulation of pro-inflamatory cytokines like monocyte chemoattractant 
protein (MCP)-1, an adipocyte-secreted protein which might play a crucial role in metabolic 
and vascular disease, in WAT [93]. The pro-inflammatory effects of eNAMPT in 
adipocytes might be mediated through the IL-6-TRAF6-NF-κB pathway[94]. NAMPT was 
also described to stimulate tumor necrosis factor alpha (TNFα) and IL-6 expression [33]. 
Furthermore, eNAMPT increased lipoprotein lipase and peroxisome proliferator-activated 
receptor gamma (PPARγ) as well as fatty acid synthase in preadipocytes and differentiated 
adipocytes, respectively, suggesting NAMPT as a regulator of lipid metabolism [95] as well 
as indicating a role of NAMPT in the development of obesity and related disorders.  
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NAMPT and liver in obesity 
NAMPT seems to play a role in the development of non-alcoholic fatty liver disease 
(NAFLD), which is the most common liver disorder in western countries. NAFLD covers 
a wide range of pathophysiological conditions from simple steatosis (hepatic lipid 
accumulation) to inflammation (non-alcoholic steatohepatitis), which frequently leads to 
fibrosis and cirrhosis accompanied with a higher risk for hepatocellular carcinoma and 
eventually the need for liver transplantation [96]. We could identify hepatocytes as a source 
of eNAMPT [70]. It was shown that NAMPT plasma concentrations correlated with portal 
inflammation in subjects with NAFLD [97]. Several, partly conflicting, studies about the 
association of NAMPT with severity of NAFLD have been published during the following 
years and are summarized in table 2, with NAMPT up and down regulation both being 
observed in animal models or human subjects with NAFLD. In the liver, NAMPT is 
regulated by FoxO transcription factors, that are part of the insulin signaling network and 
implicated in the regulation of adipogenesis and gluconeogenesis [98]. Liver specific 
(FoxO)-1, 3 and 4 knockout mice were shown to have increased hepatic triglyceride and 
reduced NAMPT levels. Overexpression of NAMPT significantly reduced hepatic 
triglycerides in vivo [43]. Another regulator of NAMPT is miRNA-34a that was shown to be 
elevated in obese subjects and significantly reduced NAD levels and SIRT1 activity in the 
liver by directly targeting NAMPT mRNA expression. In diet-induced obese mice 
inhibition of miR-34 restored Nampt and NAD levels and improved steatosis, 
inflammation, and glucose intolerance [99]. Apoptosis was shown to be improved in stress-
exposed hepatocytes if NAMPT was over expressed. Furthermore, pharmacological 
activation of peroxisome proliferator-activated receptors (PPAR) α, which is up regulated 
in patients with NAFLD and is a major regulator of lipid metabolism in the liver, led to 
attenuated Nampt levels in rat hepatocytes [100]. Troxerutin, a trihydroxyethylated 
derivative of the natural bioflavonoid rutin, prevented obesity, liver steatosis and injury in 
high-fat diet treated mice by enhancing Nampt protein and NAD levels, decreasing Parp 
protein levels and restoring Sirt1 activity [101]. Supplementation of leucine, an essential 
amino acid, improved Nampt and Sirt1 protein levels as well as NAD levels in high-fat diet 
fed mice. This effect was underlined by a decrease of the acetylation status of the Sirt1 
targets PPARγ coactivator 1-alpha (PGC-1α) and FoxO1 suggesting improved 
mitochondrial biogenesis as well as insulin sensitivity and glucose metabolism, respectively 
[102]. In contrast, a pro-inflammatory action of NAMPT was found in HepG2 cells. When 
treated with palmitate a time-and dose-dependent increase of NAMPT mRNA and protein 
expression as well as mRNA expression of IL-6 and TNFα was found while a down 
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regulation of NAMPT counteracted the inflammatory response. By inhibition of NF-κB, 
NAMPT protein levels were normalized after stimulation with palmitate. This indicates 
that NAMPT might play a role in palmitate-induced inflammation in hepatocytes through 
the NF-κB pathway [103]. Another in vitro study using HepG2 cells showed that eNAMPT 
activated gluconeogenesis via activation of phosphoenolpyruvate carboxykinase and 
glucose-6-phosphatase, which did not depend on SIRT1 activation [64]. 
Taken together, NAMPT is able to modulate important processes in the pathogenesis of 
NAFLD by regulating oxidative stress (or mitochondrial biogenesis), apoptosis, lipid and 
glucose metabolism, inflammation and insulin resistance. 
 
2.3 NAMPT and type 2 diabetes (T2D) 
The increasing prevalence of obesity is contributing substantially to the ongoing epidemic 
of T2D [104, 105]. It is well demonstrated that increased abdominal adiposity is associated 
with low-grade inflammation, abnormal hormone secretion and various metabolic 
disturbances that contribute to the genesis of insulin resistance [104, 105]. Recently, there 
has been a growing interest on the role of different adipokines in the pathogenesis of 
metabolic complications related to obesity [106, 107]. In particular, in the large spectrum of 
adipokines, NAMPT represents one of the most promising and interesting molecules that 
seems directly implicated in the regulation of glucose-stimulated insulin secretion (GSIS) in 
pancreatic β cells [17].  
 
NAMPT and T2D in animal models 
While some studies explained the effects of Nampt on glucose metabolism by the 
controversial finding of insulin-mimetic actions of Nampt [108], others focused on Nampt 
as NAD biosynthetic enzyme. Circulating levels of the Nampt product NMN and 
consequently NAD levels in beta cells/islets were significantly lower in old beta cell-
specific Sirt1-overexpressing (BESTO) mice compared to young BESTO mice. NMN 
administration restored the positive effect of Sirt1 on glucose tolerance and glucose-
stimulated insulin secretion (GSIS), at least in the aged BESTO female mice [109]. A defect 
in NAD biosynthesis and GSIS was found in islets of Nampt+/- mice and an impaired 
glucose tolerance in Nampt+/- female mice. These alterations in glucose metabolism were 
ameliorated after the administration of NMN, one of the products of Nampt enzymatic 
reaction and a key NAD intermediate. This result suggested that the observed defects in 
GSIS were due to a reduction of Nampt -mediated NAD biosynthesis. To confirm these 
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data, FK866, a potent NAMPT inhibitor, significantly inhibited NAD biosynthesis and 
GSIS in wild-type islets, while administration of NMN restored normal NAD biosynthesis 
and GSIS in FK866-treated wild-type islets. Taken together, these findings strongly suggest 
that Nampt is able to control the regulation of insulin secretion by Nampt-mediated NAD 
biosynthesis in pancreatic beta cells [17]. Confirming this hypothesis, we demonstrated that 
NAMPT and NMN were able to induce a 2.0- and 1.8-fold increase of insulin secretion 
compared to glucose alone in human islets after 1 h incubation with high glucose 
concentration [110]. In a high-fat diet mouse model, a direct effect of Nampt not only in 
glucose metabolism but also in the pathogenesis of T2D was found. Nampt-mediated 
NAD biosynthesis was shown to be impaired in high-fat diet mice with diabetes compared 
to regular chow-fed control healthy mice, while the administration of NMN ameliorated 
glucose intolerance by restoring NAD levels. In addition, NMN augmented hepatic insulin 
sensitivity and other biological pathways related to oxidative stress, inflammation and lipid 
metabolism [111]. Fructose-rich diet (FRD)-fed mice showed increased levels of Nampt in 
brown and white adipose tissue but significantly lower levels of circulating Nampt. 
Administration of NMN abolished the suppressive effects of FRD on insulin secretion. 
NMN also showed protective effects against pro-inflammatory cytokine-mediated islet 
dysfunction. Insulin secretion in islets cultured with pro-inflammatory cytokines was 
restored by NMN. The anti-inflammatory effects of NMN were partially blocked by 
inhibition of Sirt1 [112]. Another NAD intermediate, NR, was also found to be beneficial 
by ameliorating NAD levels. HFD-induced body weight gain in mice was significantly 
attenuated by NR which was due to enhanced energy expenditure [113]. In contrast to 
NMN there are three clinical trials registered for NR (ClinicalTrials.gov) such as measuring 
serum NR and metabolites of NR (NCT02300740), analysing NR and its metabolites in 
urine and blood (NCT02191462) or investigating the insulin sensitivity and substrate 
metabolism in obese men after a 3 months treatment with NR (NCT02303483). 
 
NAMPT and T2D in humans 
Recently there has been a growing body of evidence showing a possible association 
between NAMPT levels and T2D in obese and non-obese patients [114–116]. Several 
studies reported that subjects with T2D presented significantly higher levels of NAMPT 
compared to healthy controls, independently of body mass index or adipose tissue. In 
addition, all these studies confirmed with multiple logistic regression analysis that NAMPT 
could be considered as an independent factor for T2D, even after adjustment for other risk 
factors [115, 117, 118]. In order to define the relationship between NAMPT and beta cell 
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impairment, levels of NAMPT were compared in three different groups: adult patients with 
type 1 diabetes, patients with T2D and healthy controls. In this study the authors reported 
that circulating NAMPT was significantly increased in type 1 diabetics as compared to T2D 
and non-diabetic subjects, underlining a possible inverse relationship between deterioration 
of beta cell function and NAMPT levels [119]. Although these data are very interesting, 
some limitations of this study need to be considered. In particular, the cross-sectional 
design permits to identify only a correlation between variables, but not any direct cause and 
effect. Therefore, it would be interesting to measure changes of plasma NAMPT levels in 
obese subjects during different stages of diabetes development to further clarify the role of 
this adipokine in the pathogenesis of T2D.  
 
NAMPT and T2D comorbidities 
More recently it was found that NAMPT not only is involved in the pathogenesis of beta 
cell dysfunction and diabetes but it also seems to play an important role in diabetes 
complications [106, 120]. In particular, patients with T2D were shown to present increased 
levels of NAMPT compared with controls, but more interestingly a significant correlation 
between NAMPT and signs of endothelial dysfunction have been proposed [120]. In 
addition, NAMPT levels were also increased in other complications such as diabetic 
nephropathy or lipid impairments [116]. A possible association between different NAMPT 
polymorphisms and T2D or T2D-related complications [29, 121] was reported. A higher 
frequency of NAMPT -948G/G genotype could be observed in T2D patients compared 
with controls. Furthermore, the frequency of this genotype was significantly higher in T2D 
patients with cardiovascular disease than in those without [121]. Human studies on the 
association of NAMPT with diabetes published during the last five years are summarised in 
table 3. All these evidences in in vitro and in vivo models demonstrated the powerful role of 
NAMPT in the pathogenesis of diabetes and in the development of diabetes related 
complications. More interestingly, in vitro studies reported an important role of NMN in the 
amelioration of beta cell function and in cellular homeostasis, glucose metabolism and 
stress responses.  
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Table 3: NAMPT and T2D. 
NAMPT  NAMPT correlates with  
↑ NAMPT in obese patients with 
T2D (n=19) vs non obese (n=37) 
with T2D vs controls (n=19) 
  
BMI (r=0.434; p<0.001), WHR (r=0.280; p=0.015), FPG 
(r=0.283; p=0.014), HOMA-IR (r=0.357; p=0.002), TG 
(r=0.282; p=0.014), TC (r=0.278; p=0.016), IL-6 (r=0.431; 
p<0.0001), vaspin (r=0.505; p<0.0001) [117] 
 
↑ NAMPT in obese patients with 
T2D (n=61) vs controls (n=59) 
Multiple linear regression for NAMPT and T2D: 
 Model adjusted for age, gender  
(OR=3.247; 95%CI 1.426–7.394; p=0.005) 
 Model adjusted for age, gender, BMI, WHR 
(OR=2.320;  95%CI 1.000–4.695; p=0.043) 
 Model adjusted for age, gender, BMI, WHR, SBP, DBP 
(OR=2.895;  95%CI 1.113–7.529;  p=0.029)  
 Model adjusted for age, gender, BMI, WHR, SBP, DBP, lipid 
profile, smoking status 
(OR=5.534; 95%CI 1.605–19.079 p=0.007) [118] 
 
↑ NAMPT in type 1 diabetic 
patients with long-standing disease 
(n=58) and in T2D patients 
(n=64) vs nondiabetic 
subjects(n=118) 
 
 
↑ NAMPT in patients with long-
standing disease type 1 diabetic 
(n=58) vs  patients T2D (n=64) 
In nondiabetic subjects with 
  Acute insulin response to glucose (r=0.27, p=0.002)  
  30-min OGTT insulin (r=0.24, p=0.005) 
  Fasting insulin (r=0.20, p=0.042)  
  Insulin sensitivity (r=0.19, p=0.043) 
 
In subjects with type 2 diabetes  
  HbA1C (β= 0.457, p=0.0001) 
 
In subjects with type 1 diabetes  
  Age (but not sex, BMI, or HbA1C) (β=0.344, p= 0.010) 
no correlation between serum visfatin concentration and   
HbA1C in type 1 diabetic subjects (r=0.17, p=0.20) [119]  
  
↑ NAMPT in patients with T2D 
(n=85) and minor (<500 mg/day) 
or severe proteinuria (n=45) (≥500 
mg/day) vs with age- and sex-
matched controls (n=38) 
↑ NAMPT in patients with T2D 
and severe proteinuria (n=45) 
(≥500 mg/day) vs patients with 
T2D and minor proteinuria (n=40) 
(<500 mg/day) 
 
 In subjects with type 2 diabetes  
Proteinuria (r= 0.46, p<0.0001) 
Flow mediated dilatation (r=-0.47; p<0.001) [120] 
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↑ NAMPT in patients with T2D and 
CAD (n=195) compared to subjects 
with T2D without CAD (n=56) 
 
± NAMPT in non-diabetic 
subjects with or without CAD 
(n=98) 
 
prevalence of CAD in type 2 diabetic patients by tertiles of   
plasma NAMPT was 57% (T1), 67% (T2) and 75% (T3) 
Positive association between highest tertile of plasma NAMPT 
and CAD: 
OR 2.09, 95% CI 1.11 – 4.01, p = 0.02 (T3 vs T1) 
OR 1.62, 95% CI 0.83 – 3.19, p = 0.15 (T3 vs T2) 
OR 1.29, 95% CI 0.68 – 2.44, p = 0.42 (T2 vs T1) 
 T-allele of rs9770242 NAMPT gene polymorphism was 
associated with CAD in Brazilian cohort (OR 1.46, 95% CI 1.06 
- 2.01, p = 0.02) while no association was observed in North-
American cohort [29] 
↑ NAMPT in patients T2D  
(n=44) without CVD and (n=46) 
with CVD vs healthy control 
subjects (n=60) 
↑ NAMPT in T2D patients with 
CVD and with NAMPT -948G/T 
polymorphism vs T2D with CVD 
and without NAMPT -948G/T 
polymorphism  
 NAMPT -948G/G genotypes and G alleles significantly  
associated with T2DM  (OR 2.94, 95% CI 1.06 – 8.17, p = 
0.039) and CVD in diabetic patients (OR 3,56,  95% CI 1.10 – 
11,51, p = 0.034) [121] 
   
 
↑up and ↓down regulation of NAMPT; ± no change 
BMI: body mass index, WHR: waist to hip ratio, FPG: fasting plasma glucose, HOMA-IR: 
homeostatic model assessment – insulin resistance, TG: triglycerides, TC: total cholesterol, OR: 
odds ration, CAD: coronary artery disease, CI: confidence interval, SBP: systolic blood pressure, 
DBP: diastolic blood pressure, OGTT: oral glucose tolerance test, HbA1C: glycated hemoglobin, 
CVD: coronary vascular disease 
 
2.4 NAMPT in senescence, aging and cancer 
NAMPT in aging 
Sirtuins have been comprehensively investigated as mediators of longevity [122]. NAMPT 
as a regulator of sirtuin function has been shown to delay cellular senescence by increasing 
oxidative stress resistance in human vascular smooth muscle cells [123]. In contrast, 
extracellular NAMPT induced telomere damage and premature senescence in human 
endothelial cells by activation of NADPH oxidase [124].Reduced levels of Nampt and 
NAD have been shown in peripheral tissue of aging mice, such as pancreas, WAT and 
skeletal muscle. In this study evidence was provided that administering of the Nampt 
enzyme product, NMN, could be an effective intervention to treat the pathophysiology of 
age-induced T2D [111]. Interestingly, aging also reduced Nampt-mediated NAD 
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biosynthesis in the brain, particularly in the hippocampus, affecting the function of 
neuronal stem neural stem/progenitor cells (NSPC). Aging is one of the strongest negative 
regulators of adult NSPC proliferation [125]. NSPC possess the ability to proliferate and 
differentiate into major cells of the brain, such as produce neurons, oligodendrocytes or 
astrocytes. Thus, they contribute to cognitive function and can be reactivated in the aged 
brain [125]. In this study, Nampt was shown to be involved in the molecular mechanism 
that leads to the decline of NSPC during aging. The authors raised the idea of a long-term 
NMN administration that may counteract age-related declines in NSPC functionality [126]. 
A study on young and old Wistar rats demonstrated that Nampt levels were 
decreased in the aged group. Interestingly, the age-associated decrease in Nampt and NAD 
levels were reversed with regular exercise, leading to increased specific activity of Sirt1 [52]. 
A recent clinical study on a large population of elder people investigated the relationships 
between circulating NAMPT levels, nutritional status, and insulin resistance. They found 
that plasma NAMPT levels decline with age and are related to nutritional status, especially 
visceral obesity, and inflammation [127]. 
There are several theories trying to explain the decline of NAMPT and NAD in 
aging. As discussed above, NAMPT is a major output of the circadian transcription factors 
BMAL and CLOCK [40]. One hypothesis is that a decline in central and peripheral 
circadian function during aging would result in a deficit in NAMPT and NAD production. 
Aging is accompanied by a state of chronic, low-grade inflammation, which is a major 
contributor to the development of many age-related chronic disorders. Interestingly, it has 
been shown that TNF-α, one of the major inflammatory cytokines, and oxidative stress 
significantly reduce NAMPT and NAD levels in primary hepatocytes [111]. TNF-α also 
suppresses CLOCK/BMAL-mediated clock gene functions in mice [128]. This in turn may 
be another reason why NAMPT-mediated NAD biosynthesis is decreased during aging. As 
mentioned above, chronic inflammation, oxidative stress and DNA damage are crucial 
players associated with aging. The activation of NAD-dependent PARPs is induced 
immediately after DNA damage to facilitate repair and maintenance of genomic integrity. 
Thus, acute DNA damage can induce a sudden depletion of NAD due to PARP activation. 
During aging, damaged DNA accumulates in the nucleus, causing PARP activation and 
might be another possible explanation for age-induced NAD reduction. Most recently, 
several studies on whole-body Sirt6 transgenic mice or brain-specific Sirt1 overexpression 
demonstrated the importance of sirtuins in aging [129, 130]. 
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NAMPT in cancer 
NAMPT-mediated NAD production is essential for cellular metabolism, energy 
production, and DNA repair - processes that undergo crucial changes during malignant 
transformation. Cancer cells possess a high glucose uptake and an increased rate of aerobic 
glycolysis. These metabolic alterations require increased amounts of the redox co-factor 
NAD. There is a strong body of evidence that cancer cells have a higher NAD turnover 
than normal cells due to their increased energy demand used for cell proliferation and 
DNA repair. As mentioned above, NAD functions in many critical cellular events that are 
necessary for cancer cell growth, including transcriptional regulation, cell cycle progression, 
apoptosis, DNA repair, chromatin dynamics regulation and telomerase activity [59]. As 
NAD is rapidly consumed in cancer cells and converted to nicotinamide, NAMPT is 
essential for the replenishment of the intracellular NAD pool. Therefore, the development 
of many cancers is associated with increased NAMPT expression including colorectal, 
ovarian, breast, gastric, prostrate, well-differentiated thyroid, and endometrial carcinomas, 
myeloma, melanoma and astrocytomas [131]. Recently, we could show that NAMPT is 
differentially expressed in hepatocarcinoma cell lines as compared to non-cancerous human 
hepatocytes. Resveratrol treatment of hepatocarcinoma cell lines led to decreased NAMPT 
activity and cell death, while in non-cancerous human hepatocytes NAMPT activity and 
NAD levels were increased upon incubation with resveratrol [71]. In a meta-analysis of 
genome-wide expression data to identify NAMPT-influenced genes, a reduced NAMPT 
expression was found to strongly dysregulate cancer biology signaling pathways [132]. 
Cancer cells were demonstrated to be more susceptible to NAMPT inhibition than normal 
cells [133, 134]. 
Clinical studies also demonstrated that serum or blood levels of NAMPT were 
found to be increased in cancer patients with a positive correlation between either tissue or 
circulating levels and stage progression [34, 135–137]. However, the molecular mechanism 
of eNAMPT on carcinogenesis is far from clear. A recent study demonstrated that 
eNAMPT affected redox adaptive responses and promoted tumor proliferation in human 
malignant melanoma cells [138]. Furthermore, cell lines overexpressing NAMPT were 
significantly more resistant to chemotherapeutic agents than control cells [139]. In contrast, 
stable NAMPT knock-down cells were shown to be more sensitive to such treatment than 
controls [16]. NAMPT was shown to activate the MAPK/ERK pathway and to stimulate 
the vascular endothelial growth factor (VEGF) promoting angiogenesis, a crucial process 
during tumor growth and expansion. Targeting NAMPT activity represents a novel 
therapeutic strategy for human cancers. For example, the specific NAMPT inhibitor 
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FK866 has been evaluated in a broad variety of tumors, including solid tumors and 
leukemia [140–142] in vitro and nude mouse xenografts [25, 140, 143–145], in which FK866 
was able to reduce or attenuate tumor growth. NAMPT inhibition attenuated glycolysis in 
conjunction with the reduction of NAD levels and led to a blockade of the pentose 
phosphate pathway, serine biosynthesis, and the tricarboxylic acid cycle [145]. In a recent 
study, we could demonstrate that FK866 induced delayed energy stress in hepatocarcinoma 
cells that triggered the activation of AMPK and down regulated mTOR signaling which 
was associated with increased cancer cell death. Non-cancerours human hepatocytes were 
less sensitive to FK866 [146]. Clinical trials applying NAMPT inhibitors as monotherapy 
(summarised in table 4) have so far been less promising. One possible explanation could 
be the action of CD38 or CD73 reversing cell death induced by NAMPT inhibition 
through the supply of ectocellular NAD precursors [147]. However, combining FK866 or 
other NAMPT inhibitors with antineoplastic agents, chemotherapy or radiotherapy might 
enhance their therapeutic efficacy. 
 
Table 4: Clinical trials inhibition of NAMPT  
 
Inhibitor 
 
 
CHS 828: CHS 828 in Treating Patients With Solid Tumors (Phase 1) 
 ClinicalTrials 
Identifier: 
NCT00003979 
 
 Condition: Unspecified Adult Solid Tumor, Protocol Specific 
 Status: This study has been withdrawn prior to enrollment. 
   
   
 Safety and efficacy of NAD depleting cancer drugs: results of a phase I 
clinical trial of CHS 828 and overview of published data. (Phase 1) [167] 
  
 Condition: advanced solid tumours 
 Status: This study has been completed.  
   
   
GMX1777: A Phase I/II Study of GMX1777 in Combination With Temozolomide for 
the Treatment of Metastatic Melanoma (Phase 1; Phase 2) 
 ClinicalTrials 
Identifier: 
NCT00724841 
 
 Condition: Metastatic Melanoma 
 Status: This study has been terminated.  
(Study terminated prematurely due to financial 
contraints.) 
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Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid 
Tumors or Lymphomas (Phase 1) 
 ClinicalTrials 
Identifier: 
NCT00457574 
 
 Condition: Solid Tumors and Lymphomas 
 Status: This study has been withdrawn prior to enrollment.  
(Study terminated prematurely due to financial 
constraints.) 
     
     
APO866 
(FK866) 
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma 
(Phase 2) 
 ClinicalTrials 
Identifier: 
NCT00431912 
 Condition: Cutaneous T-cell Lymphoma 
 Status: This study has been completed. (No study results 
posted) 
     
     
 A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the 
Treatment of Refractory B-CLL (Phase 1; Phase 2) 
 ClinicalTrials 
Identifier: 
NCT00435084 
 
 Condition: B-cell Chronic Lymphocytic Leukemia 
 Status: This study has been completed. (No study results 
posted) 
     
     
 A Study to Assess APO866 for the Treatment of Advanced Melanoma 
(Phase 2) 
 ClinicalTrials 
Identifier: 
NCT00432107 
 
 Condition: Melanoma 
 Status: This study has been completed. (No study results 
posted) 
   
   
 The pharmacokinetics, toxicities, and biologic effects of FK866, a 
nicotinamide adenine dinucleotide biosynthesis inhibitor[168] 
  
 Condition: advanced solid tumor malignancies refractory to 
standard therapies 
 Status: This study has been completed.  
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2.5 Conclusions 
 By regulating intracellular NAD concentrations NAMPT is involved in regulating 
cellular energy metabolism. 
  NAD concentrations are decreased in various metabolic disorders and during aging. 
 Application of NAD precursors seems to be successful in augmenting NAD levels 
under pathophysiological conditions and aging. 
 NAMPT regulates glucose-stimulated insulin secretion (GSIS) in pancreatic beta cells. 
 NAMPT regulates central pathogenic mechanisms during the progression of NAFLD. 
 NAMPT plays a crucial role in cancer cell metabolism and is often overexpressed in 
tumor tissues. 
 
2.6 Open questions 
 Are there other functions besides the regulation of NAD concentrations for 
intracellular NAMPT? 
 How is NAMPT secretion regulated and what is the role of circulating 
NAMPT/eNAMPT? 
 Is eNAMPT enzymatically active under pathophysiological conditions? 
 Does NAMPT expression and function depend on disease progression and severity in 
metabolic disorders? 
 Why does NAMPT inhibition lead to cell death and tumor remission in vitro and in 
animal models, but not in clinical trials? 
 
 
 
 
Detailed author contributions can be found at the end of this work.  
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Background: Nicotinamide phosphoribosyltransferase (NAMPT) is the key enzyme of the NAD 
salvage pathway starting from nicotinamide. Cancer cells have an increased demand for NAD due 
to their high proliferation and DNA repair rate. Consequently, NAMPT is considered as a putative 
target for anti-cancer therapies. There is evidence that AMP-activated protein kinase (AMPK) and 
mammalian target of rapamycin (mTOR) become dysregulated during the development of 
hepatocellular carcinoma (HCC). Here, we investigated the effects of NAMPT inhibition by its 
specific inhibitor FK866 on the viability of hepatocarcinoma cells and analysed the effects of 
FK866 on the nutrient sensor AMPK and mTOR complex1 (mTORC1) signaling. 
Results: FK866 markedly decreased NAMPT activity and NAD content in hepatocarcinoma cells 
(Huh7 cells, Hep3B cells) and led to delayed ATP reduction which was associated with increased 
cell death. These effects could be abrogated by administration of nicotinamide mononucleotide 
(NMN), the enzyme product of NAMPT. Our results demonstrated a dysregulation of the 
AMPK/mTOR pathway in hepatocarcinoma cells compared to non-cancerous hepatocytes with a 
higher expression of mTOR and a lower AMPK activation in hepatocarcinoma cells. We found that 
NAMPT inhibition by FK866 significantly activated AMPKα and inhibited the activation of mTOR 
and its downstream targets p70S6 kinase and 4E-BP1 in hepatocarcinoma cells. Non-cancerous 
hepatocytes were less sensitive to FK866 and did not show changes in AMPK/mTOR signaling 
after FK866 treatment. 
Conclusion: Taken together, these findings reveal an important role of the NAMPT-mediated 
NAD salvage pathway in the energy homeostasis of hepatocarcinoma cells and suggest NAMPT 
inhibition as a potential treatment option for HCC.   
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3.1 Introduction 
The co-factor nicotinamide adenine dinucleotide (NAD) plays a crucial role in multiple 
cellular processes and is substrate for a variety of enzymes and regulatory proteins [1]. In 
humans a main portion of NAD is generated via the nicotinamide (NAM) salvage pathway, 
in which nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate-limiting step 
in the biosynthesis of NAD yielding nicotinamide mononucleotide (NMN) [2;3]. As NAD 
is rapidly consumed in cells (1h) and converted to NAM [4], NAMPT is essential for the 
replenishment of the intracellular NAD pool. The development of many cancers is 
associated with increased NAMPT expression [5]. Cancer cells have a high rate of NAD 
turnover due to their increased energy demand and a high activity of NAD-dependent 
enzymes, such as poly (ADP-ribose) polymerases (PARPs), mono-ADP ribosyltransferases 
(MARTs) and sirtuins, required for DNA repair, genome stability and proliferation [1;5]. 
Therefore, cancer cells are more susceptible to NAMPT inhibition than normal cells [6;7]. 
In previous studies, we found that NAMPT is released from hepatocytes [8] as well as 
differentially expressed and more enzymatically active in hepatocarcinoma cells compared 
to non-cancerous human hepatocytes [9]. Hepatocellular carcinoma (HCC) is the second 
leading cause of cancer-related deaths [10]. The only available proven systemic therapy for 
HCC is the multi-targeting kinase inhibitor sorafenib [11]. An effective second-line agent 
for patients with sorafenib failure or intolerance has yet to be identified. This has led to an 
intensive search for molecular pathways and novel compounds for the treatment and 
prevention of HCC. Targeting NAMPT activity and intracellular NAD content represents a 
novel therapeutic concept for HCC. The specific NAMPT inhibitor FK866 is a 
competitive inhibitor that was selected by an anticancer screening system differentiating 
acute cytotoxicity from growth inhibition [12;13]. FK866 has been evaluated in a broad 
variety of tumors, including solid tumors and leukemia [14-16] in vitro and in nude mouse 
xenografts [17-19], where FK866 was able to reduce or attenuate tumor growth. 
In HCC tissue, AMP-activated protein kinase (AMPK), a major regulator of cellular 
energy homeostasis that coordinates multiple metabolic pathways, has been shown to be 
dysregulated compared to normal tissue [20;21]. AMPK activity opposes tumor 
development and negatively regulates the Warburg effect (aerobic glycolysis) leading to 
suppression of tumor growth in vivo [20-22]. AMPK translates changes in glucose 
availability and fluctuation of energy to mammalian target of rapamycin (mTOR) and 
thereby acts as a master energy sensor to modulate cellular activities in response to energy 
stress [23;24]. mTOR, a serine/threonine protein kinase, has been observed to be increased 
in multiple human cancers, including HCC, where it is associated with less differentiated 
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tumors, earlier tumor recurrence, and worse survival outcomes [25;26]. Inhibition of 
mTOR has proven efficacious in clinical trials [26;27]. Recently, there is great scientific 
interest in finding molecular pathways and novel compounds that target AMPK/mTOR 
signaling as a new treatment option for HCC.  
Little is known about the interaction of NAMPT and AMPK/mTOR signaling 
during the development of HCC. In this study, we investigated the effects of the NAMPT 
inhibitor FK866 on hepatocarcinoma cells and non-cancerous human hepatocytes. We 
asked whether or not FK866-induced energy stress might activate AMPK and modify the 
mTOR signaling pathway and whether the observed effects could be rescued by the 
NAMPT enzyme product NMN. 
 
3.2 Material and Methods 
Material 
Cell culture media, supplements and antibiotics were obtained from PAA (Cölbe, Germany) 
or Invitrogen (Karlsruhe, Germany). FK866, nicotinamide mononucleotide (NMN) and 
camptothecin were purchased from Sigma-Aldrich (Munich, Germany). Etoposide was 
purchased from Merck Millipore (Darmstadt, Germany).  
 
Hepatocarcinoma cell lines  
Huh7 cells (p53-mutated) and Hep3B cells (p53-deficient) were maintained in DMEM 
medium with high glucose or MEM medium, repectively. Media were supplemented with 
10% fetal bovine serum (FBS), 2mM glutamine, 100IU penicillin and 100µg/mL 
streptomycin. All cells were grown at 37°C in a humidified atmosphere of 95% air and 5% 
CO2.  
 
Primary human hepatocytes 
Tissue samples from patients undergoing liver surgery at the University Medical Center 
Regensburg were used. Primary human hepatocytes (PHH) were isolated and cultivated as 
described recently [28]. Briefly, non-neoplastic tissue samples from liver resections were 
obtained from patients undergoing partial hepatectomy for metastatic liver tumors of 
colorectal cancer. PHHs were isolated using a modified two-step EGTA/collagenase 
perfusion procedure and plated on collagen coated dishes. Experimental procedures were 
performed according to the guidelines of the charitable state controlled foundation HTCR 
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(Human Tissue and Cell Research, Regensburg, Germany), with the informed patient's 
consent approved by the local ethical committee of the University of Regensburg. All 
experiments involving human tissues and cells have been carried out in accordance to The 
Code of Ethics of the World Medical Association (Declaration of Helsinki). Cells were seeded in 
Williams' Medium E containing 2mM glutamine, 10-7mol/L dexamethasone, 100IU 
penicillin, 100µg/mL streptomycin and 10%FBS. All cells were grown at 37°C in a 
humidified atmosphere of 95% air and 5% CO2.  
 
Cell treatments 
FK866 was dissolved in DMSO to create a stock solution of 10mM. NMN was dissolved 
in the appropriate medium for a stock solution of 100mM. After 16h serum starvation, 
cells were treated with the indicated concentration of FK866 alone or in combination with 
NMN [500µM] for 24, 48 and 72h. 
 
Cell viability and apoptosis 
Cell viability analysis was conducted using the cell proliferation reagent WST-1 (Roche, 
Grenzach-Wyhlen, Germany) according to manufacturer´s instructions. To examine the 
effects of FK866 on cell death, the number of dead cells was measured by FACS analysis at 
different time points (48h, 72h) using the AnnexinV-FITC Apoptosis Detection Kit (BD 
Pharmingen™, Franklin Lakes, USA). Adherent and floating cells were analysed according 
to manufacturer´s protocol. Samples were analysed using a Beckton-Dickinson FACS 
LSRII. As positive control, apoptosis was induced via camptothecin [2µM] and etoposide 
[85µM] for 24h. Annexin+ (An+) and double-stained An+/propidium iodide (PI+) cells were 
considered as dead cells.  
 
ATP measurement 
ATP levels were measured with the luminescent-based CellTiter-Glo® Luminescent Cell 
Viability Assay (Promega, Madison, USA) according to the manufacturer’s protocol.  
 
Western Blot 
Protein extraction and Western Blot analysis were performed as described previously [9]. 
Primary antibodies used for immunoblotting included anti-phospho-AMPKα (Thr172), 
anti-AMPKα, anti-phospho-mTOR (Ser2448), anti-mTOR, anti-tubulin, anti-phospho 
p70S6 kinase (Thr389), anti-p70S6 kinase, anti-phospho-4E-BP1 (Ser65), anti-4E-BP1, 
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anti-acetylated lysine (Cell Signaling, Beverly, MA, USA) and anti-GAPDH 
(MerckMillipore, Schwalbach, Germany). Appropriate secondary antibodies were 
purchased from DAKO (Hamburg, Germany). Immunoblotting for GAPDH or tubulin 
was performed to verify equivalent amounts of loaded protein. Densitometric analysis was 
performed using ImageJ 1.41 Software (NIH, USA). 
 
NAMPT enzymatic activity  
NAMPT activity was measured by the conversion of 14C- labelled nicotinamide to 14C-
NMN using a method previously described [9;29]. Radioactivity of 14C-NMN was 
quantified in a liquid scintillation counter in counts per minute (cpm) (Wallac 1409 DSA, 
PerkinElmer). NAMPT activity (cpm) was normalized to total protein concentration as 
measured by the BCA protein assay.  
 
NAD measurement 
Concentrations of NAD from whole-cell extracts were quantified by HPLC analysis using a 
SUPELCOSIL™ LC-18-T HPLC column (Sigma Aldrich) at a flow rate of 0.8ml/min with 
100% buffer A (potassium phosphate buffer pH 6.0) from 0–2min, a linear gradient to 
85% Buffer A/15% Buffer B (100% methanol) from 2-5min, 85% Buffer A/15% Buffer B 
from 5-10min, a linear gradient to 100% Buffer A from 10–12min and 100% Buffer A 
from 12–15min. NAD was eluted as a sharp peak at 8min and quantitated based on the 
peak area compared to a standard curve and normalized to total protein concentration as 
measured by the BCA protein assay. 
 
3.3 Results 
FK866-induced NAMPT inhibition significantly decreased NAD levels in human 
hepatocarcinoma cells which could be ameliorated by NMN administration 
We stimulated hepatocarcinoma cells with FK866 [10nM] and found significantly reduced 
NAMPT activity (-74.9±8.1% in Huh7 cells, -38.1±3.7% in Hep3B cells) (Fig.1A) which 
caused a sharp decline of NAD levels (Huh7 cells 3.3± 0.3µmol/g protein [con] vs. 
0.3±0.2µmol/g protein [10nM FK866]; Hep3B cells 2.2±0.7µmol/g protein [con] vs. 
0.2±0.08µmol/g protein [10nM FK866]) (Fig.1B). Co-treatment with NMN restored 
intracellular NAD levels in all tested cell lines (Fig.1B). To investigate the sensitivity of 
non-cancerous human hepatocytes towards FK866, we used the same treatment conditions 
as for hepatocarcinoma cells and found that non-cancerous hepatocytes showed no 
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significant reduction in NAMPT activity and NAD levels at 10nM FK866 after 48h 
(Supplement Fig.1A,B).  
Emerging evidence suggests that the cellular acetylation state is associated with the 
energy state of a cell [30]. We could show that FK866-induced NAD depletion led to a 
decreased activity of NAD-dependent lysine deacetylases as measured by an increased 
global acetylation of lysine residues (+1.9-fold, p<0.001) (Fig.1C). The administration of 
NMN abrogated the FK866-induced hyperacetylation of lysine residues (p<0.001) (Fig.1C).  
Figure 1. FK866 reduced NAMPT activity and NAD content and increased global 
acetylation of lysine residues. A) NAMPT activity and B) NAD content were measured after 
24h and were normalized to total protein amount in each sample (n=3). C) Western Blot analysis of 
acetylated lysine residues in lysates of Hep3B cells treated with FK866 [10nM], a combination of 
FK866+NMN or NMN alone for 48h. GAPDH was used as loading control. Densitometric 
analysis of each lane was performed in four independent Western Blots (n=4). Cells stimulated with 
serum-free medium were used as control [con] and were set 1. Data are represented as mean± SEM 
and statistical analysis was performed using one-way ANOVA and the Bonferroni post hoc test 
(*p<0.05, **p<0.01, **p<0.001 compared to serum-free medium control; #p<0.05, ##p<0.01, 
###p<0.001 compared to FK866 [10nM]). 
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NAMPT inhibition by FK866 reduced cell viability, induced energy stress and led 
to delayed cell death in human hepatocarcinoma cells 
We could detect a decreased cell viability in hepatocarcinoma cells (-49.4±4.6% in Huh7 
cells, -20.6±2.8% in Hep3B cells) (Fig.2A) after 24h of FK866 treatment. We wanted to 
investigate whether FK866-induced NAD depletion would result in a reduction of ATP 
generation and therefore would induce cellular energy stress in hepatocarcinoma cells. 
Time course studies revealed that ATP levels were lowered in Huh7 cells (-49.6±9.5%, 
p<0.01) and Hep3B cells (-61.1±6.8%, p<0.001) after 48h of treatment with 10nM FK866 
(Fig.2B). The ATP levels further declined after 72h in Huh7 cells (-90.2±2.5%, p<0.001) 
and Hep3B cells (-91.1±1.5%, p<0.001) (Fig.2C). The co-administration of NMN could 
ameliorate ATP levels in Huh7 and Hep3B cells after 48 and 72h (Fig.2B, C). 
After 72h, subsequent to the drop of NAD levels, the effects of FK866 on cell 
death became evident when measuring An+/PI+-stained cells. Hep3B cells, a p53-deficient 
cell line, already displayed an increase in An+/PI+ cells after 48h of FK866 treatment (+1.8-
fold, p<0.01) (Supplement Fig.2A) indicating that FK866-induced cell death did not 
depend on p53 function. Huh7 cells treated with FK866 [10nM] for 72h showed a 1.5-fold 
increase in An+/PI+ cells compared to control cells (p<0.05) (Fig.2D) whereas the number 
of An+/PI+ Hep3B cells increased further (+3.0-fold, p<0.01). Co-stimulation with NMN 
ameliorated the induction of cell death in Huh7 cells (p=0.09) and completely rescued 
FK866-induced cell death in Hep3B cells (p<0.01) (Fig.2D).  
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Figure 2. FK866-induced NAMPT inhibition reduced cell viability and ATP content and 
induced delayed cell death in hepatocarcinoma cells. A) Cell viability of Huh7 and Hep3B 
cells after 24h was measured using WST1-reagent (n=4). ATP content after B) 48h and C) 72h 
treatment with 10nM FK866 (n=3). Cells stimulated with serum-free medium were used as control 
[con] and were set 100%. D) AnnexinV-FITC/PI assay of Huh7 and Hep3B cells treated with 
FK866, FK866+NMN or NMN alone for 72 h (n=3). Cells stimulated with serum-free medium 
were used as control [con] and were set 1. Representative dot plots of the AnnexinV-FITC/PI 
staining in Huh7 and Hep3B cells are shown including the percentage of viable, An+ and An+/PI+ -
cells. Data are represented as mean± SEM and statistical analysis was performed using one-way 
ANOVA and the Bonferroni post hoc test (*p<0.05, **p<0.01, **p<0.001 compared to serum-free 
medium control; #p<0.05, ##p<0.01, ###p<0.001 compared to FK866 [10nM]). 
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Dysregulation of the AMPK/mTOR signaling pathway in hepatocarcinoma cells 
compared to non-cancerous hepatocytes 
Growing evidence suggests that mTOR and AMPK dysregulation play an important role in 
hepatocellular carcinogenesis [20;31]. Therefore, we compared the protein amount of 
mTOR and its downstream target p70S6 kinase and also AMPKα activation in non-
cancerous primary human hepatocytes and hepatocarcinoma cells. An increased protein 
level of total mTOR and p70S6 kinase was found in hepatocarcinoma cells compared to 
non-cancerous hepatocytes (Fig.3A). In contrast, AMPK activation was enhanced in non-
cancerous primary human hepatocytes (PHH) compared to Huh7 and Hep3B cells despite 
equal AMPKα total protein amount (Fig.3A). This suggests that mTOR signaling and 
AMPK activation are involved in metabolic adaptation of hepatocarcinoma cells and might 
be interesting targets for prevention of cancer cell growth.  
 
FK866-induced energy stress activated AMPKα and led to inhibition of mTOR 
complex1 signaling in hepatocarcinoma cells 
To test the efficacy of FK866-induced NAD depletion to activate AMPK and inhibit the 
mTOR signaling pathway, we measured the phosphorylation state of different members of 
the AMPK/mTOR complex1 cascade. FK866 treatment increased the phosphorylation of 
AMPKα at Thr172 (+3.3-fold, p<0.01) in hepatocarcinoma cells (Fig.3B). This was 
associated with a significant down regulation of phosphorylated mTOR (Ser2448) by -
50.7±0.1% (p<0.05) and the phosphorylation of its down-stream target p70S6 kinase (by -
94.7±2.4%, p<0.001) and 4E-BP1 (by -30.0±0.1%, p<0.05) indicating reduced protein 
synthesis and cell growth (Fig.3B). 
Co-treatment with NMN [500µM] completely reversed the FK866-induced effects 
on AMPK activation and mTOR complex1 signaling inhibition suggesting that the NMN 
biosynthetic activity of NAMPT is relevant in mediating the effects of FK866. NMN alone 
had no impact on AMPK activation and mTORC1 signaling in hepatocarcinoma cells 
(Fig.3B). Non-cancerous human hepatocytes treated with equal amounts of FK866 for 48h 
did not show significant changes in AMPK activation and mTOR phosphorylation 
(Supplement Fig.1C) verifying their lower sensitivity to FK866.  
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Figure 3. Expression of mTOR and AMPK in hepatocarcinoma cells and non-cancerous 
human hepatocyes and its regulation by FK866. A) Western blot analysis of AMPK and mTOR 
expression in lysates of non-cancerous, primary human hepatocytes (PHH), Huh7 and Hep3B cells 
(n=3). B) Western blot analysis of the AMPK/mTORC1 signaling pathway in lysates of Huh7 cells 
treated with FK866 [10nM], a combination of FK866 [10nM]+NMN [500µM] or NMN [500µM] 
alone for 48h (n=3). GAPDH was used as loading control. One representative blot out of 3 
independent experiments is shown. Background-corrected densitometric values were normalized to 
control (serum-free medium). Data are represented as mean± SEM and statistical analysis was 
performed using one-way ANOVA and the Bonferroni post hoc test (*p<0.05, **p<0.01, 
**p<0.001 compared to serum-free medium control; #p<0.05, ##p<0.01, ###p<0.001 compared 
to FK866 [10nM]). 
 
3.4 Discussion 
During malignant transformation the cellular metabolism undergoes multiple molecular 
and metabolic adaptations to support cell growth and survival. NAD is a key determinant 
in cancer cell biology as it is essential for redox reactions and key component of signaling 
pathways that regulate transcription, DNA repair, apoptosis and metabolism [1]. In 
mammals, NAMPT is a main regulator of the intracellular NAD pool [2;3]. Here, we 
investigated whether or not the NAMPT inhibitor, FK866, would affect intracellular NAD 
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and ATP concentrations in hepatocarcinoma cells and consequently would be able to 
regulate the activity of the metabolic sensors AMPK and mTOR. Our study showed that 
FK866 rapidly reduced NAD levels in hepatocarcinoma cells and led to delayed ATP 
depletion which could be ameliorated by administration of NMN. Break down of ATP 
levels was associated with increased cell death. In contrast to another study [6], we 
demonstrated that FK866 reduced NAMPT activity, depleted NAD and ATP content and 
induced cell death in p53-deficient Hep3B cells suggesting that FK866-mediated cell death 
does not depend on functional p53. Our results are in line with a study performed in 
chronic lymphocytic leukemia cells [14]. In our study, especially Hep3B cells showed a high 
sensitivity to FK866 and an increased number of dead cells occurred already after 48h of 
FK866 treatment. 
Interestingly, non-cancerous human hepatocytes subjected to the same FK866 
treatment as hepatocarcinoma cells did not display reduced NAMPT activity and NAD 
content even at a FK866 concentration 10-fold of the EC50 (EC50 8.2nM) indicating a lower 
sensitivity of non-cancerous cells to FK866. This has also been described for normal blood 
cells [6;7]. Therefore, FK866 represents an interesting compound in cancer cell therapy as 
it progressively exhausts NAD content in cells with a high NAD turnover that mainly rely 
on nicotinamide and the NAMPT-mediated NAD salvage pathway as source of NAD. 
Cancer cells have a significantly higher NAD turnover than normal cells to sustain their 
rapid proliferation, relative genomic instability, permanently ongoing DNA repair, 
increased aerobic glycolysis and increased activity of NAD-dependent deacetylases 
[1;12;13]. This is in line with results of our previous study showing that the expression of 
SIRT1, a NAD-dependent deacetylase, was significantly higher in hepatocarcinoma cells 
than in non-cancerous hepatocytes [9]. 
In this study we could demonstrate that NAMPT inhibition by FK866 led to a 
sharp decline of intracellular ATP levels and therefore induced energy stress. As a key 
physiological energy sensor, AMPK is a major regulator of cellular energy homeostasis that 
coordinates multiple metabolic pathways to balance energy supply [24]. Several studies have 
shown that AMPK activators exhibit inhibitory effects on cancer cell growth [32;33]. 
AMPK is known to phosphorylate and activate tuberous sclerosis complex (TSC)2, a 
negative regulator of mTOR [34]. Therefore, the AMPK/mTOR pathway serves as a 
signaling nexus for regulating cellular metabolism, energy homeostasis, and cell growth, and 
dysregulation of each pathway may contribute to the development of HCC [20;26]. Since 
the discovery that the mTOR pathway is hyperactivated in many cancers including HCC 
[25;26;31;35], there is a great interest in finding molecular pathways and novel compounds 
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that target AMPK/mTOR signaling as novel treatment option for HCC. We could show 
that components of the mTORC1 cascade were significantly higher expressed in 
hepatocarcinoma cells than in non-cancerous hepatocytes. Additionally, our data revealed 
that the activation of AMPK was significantly decreased in hepatocarcinoma cells. Reduced 
AMPK activity has also been detected in primary human breast cancer [36] and lymphoma 
[21] cells. Thus, a dysregulated AMPK activity may represent an important regulatory step 
during tumor initiation and progression, allowing cancer cells to gain a metabolic growth 
advantage by enhancing aerobic glycolysis (Warburg effect) [21]. We made the intriguing 
discovery that FK866 acts as an AMPK activator in cancer cells potentially through its 
ability to induce cellular energy stress. Activation of AMPK was associated with a down 
regulation of the mTORC1 pathway. All FK866 induced effects could be completely 
reversed by NMN suggesting that these effects were mediated by NAD. mTORC1 
inhibition led to decreased activation of its two downstream targets, 70S ribosomal protein 
S6 kinase (p70S6K) and the eukaryotic initiation factor 4E binding protein 1 (4E-BP1). 
p70S6K and 4E-BP1 are major regulators of protein translation and cellular growth [35]. 
This contradicts a study performed in neuronal cells where FK866 or a NAMPT knock 
down was shown to reduce AMPK activation [37]. However, this can be explained by the 
use of non-cancerous neuronal cells compared to cancer cells in our study. 
In summary, our study showed the importance of the NAMPT-mediated NAD 
salvage pathway for energy homeostasis in hepatocarcinoma cells. Furthermore, FK866-
induced NAMPT inhibition led to activation of AMPK and inhibition of mTOR signaling 
suggesting a putative use of FK866 alone or as a chemotherapeutic sensitizing drug to 
reduce cancer cell growth. In every case of potential therapeutic use, administration of 
NMN as antidote may be useful to modulate or counteract FK866 toxicity. Only early 
stages of HCC are curable with today's treatment protocols, therefore new therapeutic 
strategies are urgently needed and NAMPT inhibition represents a potential novel 
treatment approach. 
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3.6 Supplementary Material 
 
Supplement Figure 1. Effects of FK866 on NAMPT activity, NAD content and 
AMPKα/mTOR activity in non-cancerous human hepatocytes. Non-cancerous primary 
human hepatocytes were stimulated with different doses of FK866 [1, 10, 100nM] in serum-free 
medium for 48h. A) NAMPT activity and B) NAD content were measured and normalized to total 
protein amount in each sample. C) Western blot analysis of mTOR expression and AMPKα 
activation were performed using specific antibodies against phospho-mTOR (Ser2448), total 
mTOR and phospho-AMPKα (Thr172). Background-corrected densitometric values were 
normalized to control (serum-free medium). Data are represented as mean± SEM of two 
independent experiments (n=2) and statistical analysis was performed using one-way ANOVA and 
the Bonferroni post hoc test. 
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Supplement Figure 2. FK866 induced cell death in Hep3B cells after 48h. A) AnnexinV-
FITC/PI assay of Hep3B cells treated with FK866 [10nM], FK866 [10nM] + NMN [500µM] or 
NMN alone for 48 h (n=3). An+ and An+/PI+- stained cells were considered as dead cells and are 
depicted in the graph. Cells stimulated with serum-free medium were used as control [con] and 
were set 1. Data are represented as mean± SEM and statistical analysis was performed using one-
way ANOVA and the Bonferroni post hoc test (**p<0.001 compared to serum-free medium 
control; ##p<0.01 compared to FK866 [10nM]).  
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Resveratrol is reported to possess chemotherapeutic properties in several cancers. In this study, we 
wanted to investigate the molecular mechanisms of resveratrol-induced cell cycle arrest and 
apoptosis as well as the impact of resveratrol on NAMPT and SIRT1 protein function and asked 
whether there are differences in hepatocarcinoma cells (HepG2, Hep3B cells) and non-cancerous 
primary human hepatocytes. We found a lower basal NAMPT mRNA and protein expression in 
hepatocarcinoma cells compared to primary hepatocytes. In contrast, SIRT1 was significantly 
higher expressed in hepatocarcinoma cells than in primary hepatocytes. Resveratrol induced cell 
cycle arrest in the S- and G2/M- phase and apoptosis was mediated by activation of p53 and 
caspase-3 in HepG2 cells. In contrast to primary hepatocytes, resveratrol treated HepG2 cells 
showed a reduction of NAMPT enzymatic activity and increased p53 acetylation (K382). 
Resveratrol induced NAMPT release from HepG2 cells which was associated with increased 
NAMPT mRNA expression. This effect was absent in primary hepatocytes where resveratrol was 
shown to function as NAMPT and SIRT1 activator. SIRT1 inhibition by EX527 resembled 
resveratrol effects on HepG2 cells. Furthermore, a SIRT1 overexpression significantly decreased 
both p53 hyperacetylation and resveratrol-induced NAMPT release as well as S-phase arrest in 
HepG2 cells. We could show that NAMPT and SIRT1 are differentially regulated by resveratrol in 
hepatocarcinoma cells and primary hepatocytes and that resveratrol did not act as a SIRT1 activator 
in hepatocarcinoma cells. 
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4.1 Introduction  
Resveratrol, a dietary polyphenol, is reported to possess both chemopreventive and 
chemotherapeutic properties in several cancers [1]. In 1997, Jang and colleagues published 
a seminal paper reporting that resveratrol is able to inhibit carcinogenesis in all three stages 
(initiation, promotion and progression) [2]. Resveratrol was shown to inhibit cell 
proliferation, induce apoptosis and cell cycle arrest in different cancer types and cancer cell 
lines [3–9]. However, only one study compared the apoptotic effects of resveratrol on 
cancer and normal cells. Baarine et al. found apoptotic effects in murine tumoral cardiac 
cells which were absent in normal cardiomyocytes [8]. The molecular mechanisms are 
currently not completely understood. SIRT1 has originally been described as a target of 
resveratrol [10] although some of the data are still controversial, especially concerning 
resveratrol acting as SIRT1 activator in cancer cells [11–13]. SIRT1 belongs to the NAD 
(Nicotinamide adenine dinucleotide) dependent histone deacetylases, called sirtuins. SIRT1 
is involved in many cellular pathways, such as cellular survival, apoptosis, cellular stress 
response and energy metabolism. An increased expression of SIRT1 has been reported in a 
variety of human cancers, including prostate, ovarian, gastric and colorectal cancer. The 
role of SIRT1 in tumorigenesis is still controversially discussed. SIRT1 has been shown to 
act as both tumor promoter and tumor suppressor [14,15]. SIRT1 was shown to 
deacetylate the tumor-suppressor protein p53 on lysine residue 382 leading to its inhibition 
and subsequent tumorigenesis [16,17]. Thus, the inhibition of SIRT1 would induce cell 
death of cancer cells by activating and acetylating p53.  
It is known that cancer cells have increased energy demands because of their rapid 
cell proliferation and increased DNA repair [18]. NAD is required for both processes [19] 
and regulates crucial biological processes, including transcription, cell cycle progression, 
DNA repair and metabolic pathways [20,21]. Therefore, cancer cells have a higher rate of 
NAD turnover than normal cells. The regeneration of intracellular NAD pools is regulated 
by NAMPT (Nicotinamide phosphoribosyltransferase). NAMPT can be found 
intracellularly (iNAMPT) and extracellularly (eNAMPT). However, neither structural 
differences between these forms nor the mechanism of NAMPT secretion are known so 
far. As an intracellular protein, NAMPT catalyses the rate-limiting step in the NAD salvage 
pathway starting from nicotinamide and yielding nicotinamide mononucleotide (NMN) 
which is then converted to NAD [22–25]. Some cancer cells maintain intracellular NAD 
levels by overexpressing NAMPT which has been shown in different cancer types, such as 
colorectal and breast cancer [26–28]. The expression and regulation of intracellular 
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NAMPT in hepatocarcinoma cells has not been characterized so far. NAMPT inhibition by 
its highly specific inhibitor FK866 induces apoptosis and/or autophagy in tumor cells [29–
32]. Moreover, previous studies pointed out that inhibition of NAMPT enzymatic activity 
by FK866 or inhibition of SIRT1 activity decreased proliferation and triggered cell death in 
cancer cells which was associated with increased acetylation of p53 (K382) [16,17,33,34].  
Here we investigated the molecular mechanisms of resveratrol-induced apoptotic 
effects on hepatocarcinoma cells and non-cancerous human hepatocytes and asked 
whether NAMPT and SIRT1 are differentially regulated in hepatocarcinoma cells and non-
cancerous human hepatocytes.  
 
4.2 Material and Methods 
Ethics Statement  
Non-cancerous primary human hepatocytes were supplied by the “virtual liver” program 
(German Federal Ministry of Education and Research) and the non-profit foundation 
HTCR, including the informed patient's consent. The use of human hepatocytes for 
research purposes was approved by the local ethics committee of the Charité University 
Berlin. Written informed consent was obtained from all patients. The Charité University 
Berlin institutional review board specifically approved this study. 
 
Material 
Cell culture media, supplements and antibiotics were obtained from PAA (Cölbe, Germany) 
or Invitrogen (Karlsruhe, Germany). Resveratrol (trans isomer), nicotinamide and 
camptothecin were purchased from Sigma-Aldrich (Munich, Germany). FK866 was kindly 
provided by TopoTarget A/S, Copenhagen, Denmark. EX527 was obtained from Cayman 
Chemical (Ann Arbor, USA), InSolution Trichostatin A (TSA) and etoposide were 
purchased from Merck Millipore (Darmstadt, Germany). Flag-SIRT1 expression vector was 
obtained from Addgene (Addgene plasmid 1791) [35].  
 
Cell culture  
HepG2 cells were purchased from Leibniz Institute DSMZ (German Collection of 
Microorganisms and Cell cultures) and Hep3B cell were kindly provided by Prof. Dr. Kurt 
Engeland (Molecular Oncology, Medical School, University of Leipzig). Cells were 
maintained in MEM medium supplemented with 10% fetal bovine serum (FBS) and 2 
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mmol/L glutamine and 100 IU penicillin and 100 µg/mL streptomycin. Primary human 
hepatocytes were isolated and cultured essentially as described [36]. Cells were seeded in 
Williams' Medium E containing 2 mmol/L glutamine, 10-7 mol/L dexamethansone, 100 IU 
penicillin and 100 µg/mL streptomycin and 10% FBS. All cells were grown at 37°C in a 
humidified atmosphere of 95% air and 5% CO2.  
 
Cell treatments 
Resveratrol was dissolved in 100% ethanol to create a stock solution of 100 mM. Cells 
were stimulated with 10/25/50/100 µM resveratrol and the equivalent amount of solvent 
control (ethanol) to exclude solvent-mediated effects. To inhibit SIRT1 and deacetylases 
other than histone deacetylases class III, we used the compound EX527 [20 µM], a cell-
permeable selective inhibitor of SIRT1 dissolved in DMSO [37] and 1 µM of TSA which 
were added to the incubation medium.  
 
Measurement of cell viability and apoptosis 
To investigate the effects on proliferation and cell viability, we used the commercial Cell 
Proliferation Reagent WST-1 (Roche, Grenzach-Wyhlen, Germany) and measured 
absorbance at 450 nm. To evaluate the effects of resveratrol on apoptosis the number of 
apoptotic cells was measured by flow cytometry using the FITC Annexin V Apoptosis 
Detection Kit (BD Pharmingen, Franklin Lakes, USA). Adherent and floating cells were 
used. 5-10 μL of Annexin V-FITC (An) and 2 μL of propidium iodide (PI) were added to 
the cell suspension. Samples were analysed using a Beckton-Dickinson FACS LSRII. As 
positive control, apoptosis was induced via camptothecin [2 µM] and etoposide [85 µM] for 
24 h. An+ and double-stained An+/PI+ cells were considered apoptotic. To exclude 
cytotoxic effects of resveratrol, we used supernatant of HepG2 cells and primary human 
hepatocytes to measure the release of the enzyme, adenylate kinase, from damaged cells. 
Therefore, we used the ToxiLight™ Non-destructive Cytotoxicity BioAssay Kit (Lonza, 
Cologne, Germany).  
 
Cell cycle distribution analysis 
PI staining was used to analyse DNA content and cell cycle distribution. After cell 
treatment, adherent and floating cells were harvested and fixed with 2 mL of 70% ethanol 
(4ºC). The cell pellet was resuspended in 50 µL PBS with 3.3 µL RNase A [30 mg/mL], 
450 µL FACS-buffer (PBS+ 2% FBS) and PI [50 µg/mL] were added to the flow 
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cytometry tubes. Cells were analysed using a Beckton-Dickinson FACS LSRII by 
measuring the PI signal in the FL2 channel.  
 
Reverse Transcription-Quantitative Real-time PCR (RTqPCR)  
To measure mRNA expression, total RNA was extracted using the RNeasy Mini Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Reverse 
transcription was performed using 200 U M-MLV reverse transcriptase (Invitrogen, 
Karlsruhe, Germany) per 500 ng or 1 µg total RNA with random hexamer [p(dN)6] 
primers. mRNA expression was quantified by real-time PCR with TaqMan probe based 
(Eurogentec, Cologne, Germany) or SYBR green based (Primerdesign, Southampton, UK) 
gene expression assay on the ABI 7500 Sequence Detection System (Applied Biosystems, 
Darmstadt, Germany). The housekeeping genes TATA-box-binding protein (TBP), 
hypoxanthine phosphoribosyltransferase (HPRT) or beta-ACTIN were quantified simultaneously. 
Sequence information of primers and probes are given in Table 1. For standardization of 
gene expression, the target gene amount was normalized to the mean of the housekeeping 
gene expression in each sample.  
 
Table 1. Sequences of Primer and Probes used for real-time PCR (TaqMan®). 
NAMPT (nicotinamide phosphoribosyltransferase, also known as PBEF, visfatin); p21; 
housekeeping genes beta-ACTIN, TBP (TATA-box-binding protein) and HPRT (hypoxanthine 
phophoribosyltransferase). 
 
 
Target Forward Primer Reverse Primer Probe 
NAMPT GCA GAA GCC GAG TTC 
AAC ATC 
TGC TTG TGT TGG GTG 
GAT ATT G 
TGG CCA CCG ACT 
CCT ACA AGG TTA 
CTC AC 
beta-
ACTIN 
CGA GCG CGG CTA CAG 
CTT 
CCT TAA TGT CAC GCA 
CGA TTT 
ACC ACC ACG GCC 
GAG CGG 
TBP TTG TAA ACT TGA CCT 
AAA GAC CAT TGC 
TTC GTG GCT CTC TTA 
TCC TCA TG 
AAC GCC GAA TAT 
AAT CCC AAG CGG 
TTT G 
HPRT GGC AGT ATA ATC CAA 
AGA TGG TCA A 
GTC TGG CTT ATA TCC 
AAC ACT TCG T 
CAA GCT TGC TGG 
TGA AAA GGA CCC 
C 
p21 CGAAGTCAGTTCCTTGT
GGAG 
CATGGGTTCTGACGGAC
AT 
- 
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Protein extraction and immunoblotting  
For protein analyses, cells were lysed in modified RIPA buffer (50 mM TrisHCl pH 7.4; 
1% NP-40; 0.25% sodium deoxycholate; 1x Roche complete proteases inhibitor cocktail; 1 
mM EDTA; 1 mM sodium orthovanadate; 1 mM sodium fluoride; 5 mM nicotinamide; 5 
µM TSA, 1mM sodium butyrate) and separated by SDS-PAGE (8-15%). Protein 
concentration of lysates was measured by BCA protein assay (Pierce, Thermo Scientific). 
After transfer to nitrocellulose membranes (Millipore, Bedford, MA, USA), blots were 
blocked with 5% (w/v) non-fat dry milk in 1x TBS buffer containing 0.1% Tween 20 
(TBS-T). Primary antibodies used for immunoblotting included anti-NAMPT clone OMNI 
379 (1:5000) (Cayman Chemical, Ann Arbor, MI, USA), anti- acetylated p53 (K382) 
(1:1000), anti-p53 (1:1000), anti-p53 (1C12) (1:1000), anti-phospho-p53 (Ser15) (1:1000), 
anti-SIRT1 (D379) (1:1000), anti-p21 (1:1000), anti-Bax (1:1000), anti-caspase3 (1:500), 
anti- cleaved caspase3 (1:500) (Cell Signaling, Beverly, MA, USA) and anti-GAPDH 
(MerckMillipore, Schwalbach, Germany). Secondary antibodies were purchased from 
DAKO (Hamburg, Germany). Immunoblotting for GAPDH was performed to verify 
equivalent amounts of loaded protein. Detection was performed using enhanced 
chemiluminescence. Densitometric analysis was performed using ImageJ 1.41 Software 
(NIH, USA). 
 
Measurement of NAMPT release  
NAMPT concentration in supernatants of HepG2 cells and primary hepatocytes was 
quantified using the human extracellular NAMPT/PBEF/Visfatin ELISA Kit (AdipoGen 
Inc., Seoul, South Korea), respectively, according to manufacturer’s instructions. NAMPT 
concentration was normalised to the corresponding total protein amount in each sample. 
For semiquantitative measurements, NAMPT levels were detected by using supernatant of 
cultured cells for Western Blot analysis.  
 
NAMPT enzymatic activity  
NAMPT activity was measured by the conversion of 14C- labelled nicotinamide to 14C-
NMN using a method previously described [38]. For preparation of lysates, cells were 
harvested and resuspended in 100 µL of 0.01 mol/L sodium phosphate buffer, pH 7.4, 
frozen at –80°C for 24 h and thawed at room temperature. Cell debris was removed by 
centrifugation at 23,000 rcf, 90 min at 0°C. Protamine sulphate solution (1% in NaHPO4 
buffer) was added to the supernatant (70 µL/mL supernatant) to precipitate DNA by 
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incubation on ice for 15 min. After centrifugation at 23,000 rcf, 30 min at 0°C, aliquots of 
the supernatant were stored at –80°C. Lysates (50µg) were added to 50 µL reaction mix (50 
mmol/L TrisHCl; 2 mmol/L ATP; 5 mmol/L MgCl2; 0.5 mmol/L PRPP; 6.2 µmol/L 14C-
nicotinamide; American Radiolabelled Chemicals, St. Louis; MO, USA) and incubated at 
37°C for 1h. Optimal conditions for the NAMPT activity assay (amount of total protein, 
incubation time, pH value) were determined (Fig.S1A,B,C). For measuring extracellular 
NAMPT activity we used supernatant of HepG2 cells and concentrated it 80-fold using 
Amicon Ultra Centrifugal Filter Units (Ultracel-50k) (Millipore). Then, 10µl of 
concentrated supernatant was used for the enzyme assay reaction mix and incubated for 2h 
at 37°C. The NAMPT enzymatic reaction was terminated by mixing with 2 mL of acetone. 
The mixture was then transferred onto acetone-pre-soaked glass microfiber filters (GF/A 
Ø 24 mm; Whatman, Maidstone, UK). After rinsing with 2x 1 mL acetone, filters were 
dried, transferred into vials with 6 mL scintillation cocktail (Betaplate Scint, PerkinElmer, 
Waltham, MA, USA) and radioactivity of 14C-NMN was quantified in a liquid scintillation 
counter in counts per minute (cpm) (Wallac 1409 DSA, PerkinElmer). NAMPT activity 
was normalised to total protein concentration as measured by the BCA protein assay. The 
validity of the assay was evaluated by adding the specific NAMPT inhibitor, FK866 
(Fig.S1C). FK866 induced a dose-dependent decrease in NAMPT activity with an IC50 
value of 8.2 nM.  
 
NAD Measurements 
Concentrations of NAD from whole-cell extracts were quantified by High-performance 
liquid chromatography (HPLC) and the NAD/NADH assay kit (EnzyChrom 
NAD/NADH Assay Kit, Biotrend, Köln, Germany), applied according to manufacturer’s 
instructions. HPLC analysis was performed with Chromaster Purospher STAR RP-18 
endcapped 3 µm Hibar RT 150-3 HPLC column (Merck). Briefly, cultured cells were 
extracted in 1M HClO4 and neutralized in 3M K2CO3 on ice as described previously [39]. 
After centrifugation for 10 min at 18,000 rcf (4°C), the supernatant was filtered and loaded 
onto the column.  For NAD measurement, the HPLC was run at a flow rate of 0,4 ml/min 
with 100% buffer A from 0-5 min, a linear gradient to 95% Buffer A/5% Buffer B (100% 
methanol) from 5-6 min, 95% Buffer A/5% Buffer B from 6-11 min, a linear gradient to 
85% Buffer A/15% Buffer B from 11-12 min, 85% Buffer A/15% Buffer B from 12-16 
min, and a linear gradient to 100% Buffer A from 16-17 min.  NAD was eluted as a sharp 
peak at 15 min and quantitated based on the peak area compared to a standard curve and 
normalised to protein content of cultured cells. 
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Plasmid transfection 
Transfection was conducted using NEON Transfection System (100µl Kit, invitrogen) 
according to the manufacturer's manual. Briefly, HepG2 cells were splitted 1:3 one day 
before transfection. Cells were transiently transfected with pECE-Flag-SIRT1 (2µg DNA/ 
0.5 x 106 cells) or the empty vector (mock-control). After 24 h of transfection, medium was 
changed for a further 24h  resveratrol-containing medium at 37 C.  
 
Statistical analyses 
Data are presented as mean ± SEM. Data were analysed for statistical significance by one-
way analysis of variance (ANOVA) followed by Bonferroni post hoc test. Differences 
between two groups were evaluated using unpaired Student’s t-test. All analyses were 
performed using GraphPad Prism 5 software (GraphPad Software, Inc., San Diego, USA). 
The level of significance for all comparisons was set at p< 0.05. 
 
4.3 Results 
NAMPT and SIRT1 are differentially expressed in hepatocarcinoma cells and 
primary human hepatocytes 
The expression levels of NAMPT and SIRT1 were evaluated using qPCR and Western Blot 
analysis. Our data revealed that NAMPT expression is lower in HepG2 (-75.6%±5.2%) 
and Hep3B cells (-84.6%±0.5%) compared to non-cancerous primary human hepatocytes 
(Fig.1A,B). In contrast, the NAD-dependent deacetylase SIRT1 is significantly higher 
expressed in both cancer cell lines compared to primary human hepatocytes (HepG2 cells 
2.8-fold, Hep3B cells 2.5-fold) (Fig.1A,B). Intracellular NAD levels in HepG2 cells and 
primary hepatocytes were not significantly different (HepG2 cells 1.9±0.3 µmol NAD/g 
protein compared to 1.7±0.3 µmol NAD/g protein in primary human hepatocytes) 
(Fig.1C, left panel). 
A comparison of the NAMPT enzymatic activity in HepG2 cells and primary 
human hepatocytes showed a 3-fold higher (p< 0.05) enzymatic activity of NAMPT in 
HepG2 cells (57.2±7.7 cpm/µg protein x h) than in primary human hepatocytes (19.3±3.8 
cpm/µg protein x h) (Fig.1C, middle panel). Additionally, we measured higher eNAMPT 
levels in the supernatant of primary human hepatocytes (3.2±0.3 ng/mg protein) than in 
HepG2 cells (0.4±0.2 ng/mg protein) (Fig.1C, right panel). 
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Figure 1. NAMPT and SIRT1 expression in hepatocarcinoma cells and primary human 
hepatocytes. A) mRNA expression and B) protein expression of NAMPT and SIRT1 in primary 
human hepatocytes (n=7), HepG2 cells (n=8) and Hep3B cells (n=3). Representative Western Blot 
is shown out of three independent experiments. Measurement of C) intracellular NAD levels (left 
panel, primary hepatocytes n=4, HepG2 cells n=6), basal NAMPT enzymatic activity (middle 
panel, primary hepatocytes n=3, HepG2 cells n=4) and extracellular NAMPT (eNAMPT) levels 
(right panel, primary hepatocytes n=3, HepG2 cells n=6) in primary human hepatocytes and 
HepG2 cells. Data are shown as mean± SEM. Difference between two groups was evaluated using 
unpaired Student’s t-test (*p< 0.05, **p< 0.01, ***p< 0.001).  
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Resveratrol induces cell cycle arrest and apoptosis in hepatocarcinoma cells 
Resveratrol has been shown to induce growth arrest and apoptosis in many different cancer 
cell lines. In the present study, we wanted to investigate whether the effects of resveratrol 
are p53-dependent. Therefore, we used HepG2 cells, known to be p53 wild-type, Hep3B 
cells, a p53 deficient cell line due to a deletion of the p53 gene, and primary human 
hepatocytes as non-cancerous hepatocyte control. Cells were treated with resveratrol as 
described above. After 24 h, hepatocarcinoma cells showed a dose-dependent decrease in 
viability (Fig.2A). Resveratrol [100 µM] markedly decreased cell viability by 45.8±2.7% (p< 
0.05) in HepG2 cells and by 63.7±3.4% (p<0.01) in Hep3B cells (Fig.2A). Primary human 
hepatocytes treated with the same concentrations of resveratrol exhibited no significant 
changes in viability (Fig.2A). 
To investigate the cause of cell viability reduction by resveratrol, we analysed cell 
cycle distribution. As shown in Fig.2B, resveratrol [25, 50 µM] caused an increase of cells in 
the S-phase ([con] 4.7±0.6%, [25 µM] 21.7±5.1%, [50 µM] 17.0±2.6%, p< 0.05) and in the 
G2/M-phase ([con] 13.7±1.8%, [25 µM] 23.9±4.2%, [50µM] 27.0±6.1%, p< 0.05) and a 
corresponding decrease of cells in the G1-phase. The cell cycle distribution was not 
significantly modified in p53-deficient Hep3B cells (Fig.S2A), which indicates that the 
resveratrol-induced cell cycle arrest is mediated by a functional p53. 
However, in both hepatocarcinoma cell lines apoptotic mechanisms were activated. 
As indicated in Fig.2C, stimulation with increasing concentrations of resveratrol led to a 
dose-dependent increase in the number of apoptotic cells in HepG2 (Fig.2C,D) and Hep3B 
cells (Fig.2C). At 100 µM resveratrol, the percentage of apoptotic cells in HepG2 cells and 
Hep3B cells increased to 40.6±5.6% (p< 0.01) and to 32.2±3.7% (p< 0.05), respectively. 
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Figure 2. Resveratrol reduces cell proliferation and induces cell cycle arrest and apoptosis 
in hepatocarcinoma cells which is absent in primary human hepatocytes. Cell viability of A) 
primary human hepatocytes (n=2), HepG2 and Hep3B cells (n=3) after stimulation with resveratrol 
for 24 h. Data were normalised to serum-free medium control which was set 1. B) Cell cycle 
distribution of HepG2 cells treated with resveratrol for 24h. A representative result is shown out of 
three independent experiments. A representative dot plot is given in Fig.S2B. C) Annexin V/PI 
apoptosis assay of HepG2 (n=3) and Hep3B cells (n=3) treated with resveratrol for 24h. D) A 
representative dot plot of the Annexin/PI staining in HepG2 cells is shown including the mean 
percentage of An+ and double An+/PI+ cells of three independent experiments. Data are shown 
as mean± SEM and statistical analysis was performed using one-way ANOVA and the Bonferroni 
post hoc test (*p< 0.05; **p< 0.01 compared to serum-free medium).  
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p53 and caspase-3 are involved in resveratrol-mediated apoptotic effects 
In HepG2 cells, resveratrol increased the phosphorylation of p53 at residue serine 15 in a 
dose-dependent manner (Fig.3A). At high concentration of resveratrol [100µM], we found 
increased cleavage of caspase-3 (Fig.3A). The activation of caspase-3 by resveratrol was 
also increased in p53-deficient Hep3B cells even at lower concentration [25, 50µM] 
(Fig.3B). These results indicate that resveratrol induces caspase-3 activation in a p53-
independent manner. Then, we stimulated primary human hepatocytes with the same 
concentrations of resveratrol and found no induction of apoptosis (Fig.3C) or cytotoxicity 
(Fig.S3A).  
Figure 3. Resveratrol activates apoptotic mechanisms in hepatocarcinoma cells. Cells were 
treated with resveratrol or serum-free medium (con) for 24h. Activation of p53 through 
phosphorylation at serine residue 15 and cleavage of caspase-3 in A) HepG2 cells, B) Hep3B cells 
and C) primary human hepatocytes were analysed by Western Blot. GAPDH was used as loading 
control. One representative blot out of at least 3 independent experiments is shown.  
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Inhibition of NAMPT and SIRT1 activity in hepatocarcinoma cells induces growth 
arrest and apoptosis  
Several studies have shown that the NAD metabolism is essential for cancer cell survival 
and proliferation [40–42]. However, little is known about the effects of resveratrol on 
NAMPT and SIRT1 activity in hepatocarcinoma cells. Human SIRT1 targets and 
deacetylates the p53 tumor suppressor protein [16,17,34]. Therefore, we investigated 
whether a specific inhibition of NAMPT and SIRT1 would affect cell survival and 
apoptotic mechanisms. We used the specific NAMPT inhibitor FK866 and the SIRT1 
inhibitor EX527 [34]. FK866 increased p53 acetylation (K382) (Fig.4A) and reduced 
HepG2 cell viability after 48h (Fig.4B). Cells treated with the SIRT1 inhibitor, EX527, 
showed also increased p53 acetylation (K382), enhanced expression of p53 downstream 
target p21/WAF1/Cip1 and activation of caspase-3 (Fig.4C).  
Figure 4. Effects of FK866 and EX527 on p53 acetylation and cell viability in HepG2 cells. 
Cells were stimulated with FK866 [10 nM] or EX527+TSA [20µM EX527+ 1µM TSA] in serum-
free medium (con). Cells treated with A) FK866 and expression of acetylated p53 (K382) after 24 h. 
B) Cell viability of HepG2 cells after stimulation with FK866 for 48h measured by WST-1 assay 
(n=4). Data were normalised to serum-free medium (con) which was set 1 (**p< 0.01; ***p< 0.001 
compared to serum free medium). C) Expression of acetylated p53 (K382), p21 protein and 
cleavage of caspase-3 were analysed in HepG2 cells treated with EX527+TSA for 24h. GAPDH 
was used as loading control. One representative blot out of 3 independent experiments is shown. 
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Resveratrol differentially regulates NAMPT enzymatic activity in hepatocarcinoma 
cells and primary human hepatocytes 
Based on our findings that an inhibition of NAMPT and SIRT1 activity induced growth 
arrest and apoptosis in hepatocarcinoma cells we then asked whether resveratrol would also 
affect NAMPT enzyme activity as well as intracellular NAD levels. We found that 
resveratrol differentially regulated NAMPT activity in hepatocarcinoma cells (Fig.5A) and 
primary hepatocytes (Fig.5B) without affecting NAMPT protein expression (Fig.5C,D). We 
measured a dose-dependently decreased NAMPT activity in HepG2 cells ([100µM] -
38.9±14.0%, p<0.01) (Fig.5A) and in Hep3B cells ([100µM] -38.5± 9.4%, p<0.05) (Fig.S4). 
In contrast, NAMPT enzymatic activity in primary hepatocytes significantly increased by 
+64.7±13.8% (p< 0.05) after stimulation with 100 µM resveratrol (Fig.5B). 
We then measured the NAD level after resveratrol treatment in HepG2 cells and 
found a trend towards reduction ([con] 2.0±0.4 µmol NAD/ g total protein, [100µM] 
1.5±0.2 µmol NAD/g total protein) (Fig.5E). In contrast, intracellular NAD levels in 
primary hepatocytes were increased by resveratrol ([con] 1.7±0.3 µmol NAD/g total 
protein, [50µM] 6.4±2.5 µmol NAD/g total protein (p< 0.05), [100µM] 5.4±1.7 µmol 
NAD/g total protein) (Fig.5F).  
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Figure 5. Resveratrol differentially regulates NAMPT and NAD levels in HepG2 cells and 
primary human hepatocytes. Cells were stimulated with resveratrol or serum-free medium (con) 
for 24 h. For measuring NAMPT enzymatic activity in A) HepG2 cells and (n=4) B) primary 
human hepatocytes (n=3), 50µg of protein lysate was used for the assay and incubated for 1h. 
Counts (cpm) were normalised to µg total protein. Lysates from C) HepG2 cells (n=3) and D) 
primary human hepatocytes (n=3) were used to measure NAMPT protein levels by Western Blot. 
Determination of intracellular NAD levels in E) HepG2 cells (n=6) and F) primary human 
hepatocytes (n=4). NAD levels were normalised to total protein amount in each sample. Data are 
shown as mean± SEM and statistical analysis was performed using one-way ANOVA and the 
Bonferroni post hoc test (*p< 0.05; **p< 0.01). 
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Resveratrol differentially regulates p53 acetylation and SIRT1 protein in 
hepatocarcinoma cells and primary human hepatocytes 
We further addressed whether resveratrol could influence p53 acetylation at lysine residue 
382, a main target site of SIRT1[16,17,34], and demonstrated that resveratrol treatment of 
HepG2 cells increased acetylation of p53 ([50µM] 12.8-fold, [100µM] 13.4-fold) (Fig.6A). 
As positive control for SIRT1 inhibition, we used the specific SIRT1 inhibitor EX527 
[34,37] (Fig.6A). In contrast, primary human hepatocytes from different donors showed a 
trend towards reduced p53 acetylation after resveratrol stimulation (Fig.6B). Since the 
acetylation of p53 activates its transcriptional activity, we analysed the expression of the 
p53 downstream target p21/WAF1/Cip1, which functions as a regulator of cell cycle 
progression. In correspondence to the acetylation state of p53 we found increased 
expression of p21 mRNA (Fig.S5A) and protein in HepG2 cells (Fig.6A). 
Primary human hepatocytes from different donors showed variable results with 
either no changes in p21 protein expression or a p21 down regulation (Fig.6B, Fig.S5B). 
Nonetheless, we can exclude an activation of p53 in primary human hepatocytes. 
Furthermore, SIRT1 protein levels in HepG2 cells were reduced at 100µM resveratrol 
(p<0.01) (Fig.6C) whereas primary human hepatocytes showed a trend towards increased 
SIRT1 protein expression at the same dose of resveratrol (Fig.6D). Due to the variability of 
primary hepatocytes the changes were not significant.  
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Figure 6. Resveratrol differentially regulates p53 acetylation and SIRT1 protein level in 
HepG2 cells and primary human hepatocytes. Acetylation of p53 (K382) in A) HepG2 cells 
(n=4) and B) primary human hepatocytes (n=3) was evaluated by Western Blot. Densitometric 
analysis of at least three independent experiments is shown. As a downstream target of acetylated 
and activated p53, the expression of p21 was analysed by Western Blot. As positive control for 
SIRT1 inhibition, EX527+TSA was used. SIRT1 protein expression was analysed by Western Blot 
in C) HepG2 cells and D) primary hepatocytes and densitometric analysis was performed. GAPDH 
was used as loading control, respectively. One representative blot out of at least 3 independent 
experiments is shown. Data are represented as mean± SEM and statistical analysis was performed 
using one-way ANOVA and the Bonferroni post hoc test (*p< 0.05, **p< 0.01, n.s. not 
significant). 
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Resveratrol induces NAMPT release in HepG2 cells  
Since NAMPT was found to be released from hepatocytes [43] we determined NAMPT 
concentrations in supernatants from resveratrol-treated HepG2 cells and primary 
hepatocytes. We measured significantly increased amounts of extracellular NAMPT in the 
supernatant of HepG2 cells treated with 50µM (4-fold) and 100 µM (19.8-fold) resveratrol 
(Fig.7A) ([con] 0.4±0.2 ng NAMPT/mg total protein, [50µM] 1.6±0.7 ng NAMPT/mg 
total protein, [100µM] 7.9±1.3 ng NAMPT/mg total protein, p< 0.001). We postulated 
that NAMPT mRNA expression may be increased following resveratrol exposure in 
HepG2 cells to maintain a steady-state of intracellular NAMPT protein level. We found a 
significantly increased NAMPT gene expression after stimulation with 50 µM (1.8-fold, p< 
0.05) and 100 µM (1.7-fold, p<0.05) resveratrol in HepG2 cells (Fig.7C). 
NAMPT release and NAMPT mRNA expression in primary human hepatocytes 
were not influenced by resveratrol (Fig.7B,D). In parallel, a cytotoxicity assay was 
performed to verify that the increase of extracellular NAMPT levels was not due to leakage 
from damaged cells (Fig.S3B). We then asked at which time point NAMPT release from 
HepG2 cells started. We found that there was a time- and dose- dependent release of 
NAMPT already starting after 6h of resveratrol exposure (Fig.S3C). NAMPT is known as a 
protein with dual function- an enzyme and a cytokine-like function. We asked whether 
NAMPT that is released after resveratrol exposure could lack NMN biosynthetic action. 
We found a remarkable decrease in extracellular NAMPT activity by 72.3±11.9% (p< 
0.001) compared to control cells in serum-free medium (Fig.7E). 
 
NMN does not protect against resveratrol-induced apoptosis in hepatocarcinoma 
cells 
Next, we investigated whether NMN would be able to ameliorate resveratrol-mediated 
effects in HepG2 cells. Interestingly, NMN did not protect from resveratrol-induced cell 
cycle arrest and apoptosis in hepatocarcinoma cells (Fig.S6A,B,C,D). Further, NMN was 
not able to abrogate p53 hyperacetylation after resveratrol treatment and to decrease 
resveratrol-induced NAMPT release in HepG2 cells (Fig.S6E,F).  
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Figure 7. Effects of resveratrol on NAMPT release and NAMPT mRNA expression. Cells 
were stimulated with resveratrol in serum-free medium for 24 h. Supernatants of resveratrol treated 
A) HepG2 cells (n=7) and B) primary human hepatocytes (n=3) were used for quantifying 
extracellular NAMPT protein amount using a specific eNAMPT ELISA. eNAMPT protein 
concentration was normalised to the total protein amount.   NAMPT mRNA expression in 
resveratrol treated C) HepG2 cells (n=5) and D) primary human hepatocytes (n=4) was quantified 
by qRT-PCR and normalised to housekeeping genes. NAMPT gene expression was then related to 
its expression in serum-free control medium (0), which was set 1. Data are represented as mean± 
SEM and statistical analysis was performed using one-way ANOVA and the Bonferroni post hoc 
test (*p< 0.05; ***p< 0.001; n.s. not significant). E)  Supernatant of resveratrol [100µM] or serum-
free medium (con) treated HepG2 cells was used to measure NAMPT enzymatic activity and 
extracellular NAMPT protein levels. Counts (cpm) measured by NAMPT enzyme assay were 
referred to densitometric data of NAMPT protein levels in the supernatant of the same sample. 
Data were then normalised to serum-free control medium which was set 1. Data are shown as 
mean± SEM. The difference between these two groups was evaluated using unpaired Student’s t-
test (***p< 0.001).  
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SIRT1 inhibition decreases NAMPT activity and induces NAMPT release  
Given that resveratrol increased p53 acetylation (K382), downregulated NAMPT activity 
and induced NAMPT secretion, we asked whether an inhibition of SIRT1 by EX527 would 
exert the same effects. Indeed, our data revealed that HepG2 cells treated with EX527 
showed the same cellular responses as cells stimulated with resveratrol, such as decreased 
NAMPT enzymatic activity (-40.3±11.5%, p<0.05) (Fig.8A) and slightly reduced 
intracellular NAD level (Fig.8B). Further, as observed in resveratrol-treated HepG2 cells, 
extracellular NAMPT levels were increased upon SIRT1 inhibition (Fig.8C). 
Figure 8. SIRT1 inhibition downregulates NAMPT activity and induces NAMPT release in 
HepG2 cells. HepG2 cells were treated with EX527+TSA [20µM EX527+ 1µM TSA] or serum-
free medium (con) for 24h. Measurement of A) NAMPT enzymatic activity (n=3). Counts (cpm) 
were normalised to µg total protein in each sample (*p<0.05).  B) NAD level were determined by 
HPLC (n=5) and normalised to total protein amount in each sample. C) Supernatant of EX527 
treated HepG2 cells was used for determination of eNAMPT level. One representative Western 
blot out of 3 independent experiments is shown. 
 
SIRT1 overexpression abrogated resveratrol- induced p53 hyperacetylation, 
NAMPT release and S-phase arrest  
Since resveratrol and NMN co-treatment did not augment resveratrol-induced p53 
hyperacetylation in hepatocarcinoma cells, we tried to overcome this effect by transiently 
overexpressing SIRT1 in HepG2 cells (Fig.9A). Our data revealed that SIRT1 
overexpression significantly decreased resveratrol- induced p53 hyperacetylation ([50µM] -
76.6±6.5%, [100µM] -69.9±15.9%, p<0.05) and its transcriptional activity in HepG2 cells 
(Fig.9B). We then investigated whether a SIRT1 overexpression would be able to abrogate 
resveratrol-induced NAMPT secretion in HepG2 cells. SIRT1 overexpressing HepG2 cells 
treated with 100µM resveratrol led to decreased eNAMPT levels in the supernatant 
compared to mock-transfected cells treated with resveratrol alone (Fig.9C). This suggests 
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that SIRT1 may play a crucial role in the mechanism of resveratrol-induced NAMPT 
secretion. Reduction in cell viability upon resveratrol treatment [100µM] was not abolished 
by SIRT1 overexpression (Fig.9D) indicating that apoptosis inducing factors were still 
activated and not dependent on SIRT1. However, the resveratrol- induced cell cycle arrest 
in the S-phase was significantly decreased after SIRT1 overexpression ([con] 7.4±0.9%, 
[con+25µM] 28.1±2.6%, [Flag-SIRT1+25µM] 18.5±3.8%; [con+50µM] 26.6±3%, [Flag-
SIRT1+50µM] 17.1±3.2%) (Fig.9E).  
Figure 9. SIRT1 overexpression in HepG2 cells reversed resveratrol-induced SIRT1 
inhibition, NAMPT release and S-phase arrest. A) SIRT1 was transiently overexpressed in 
HepG2 cells [2.0µg plasmid/ 0.5x106 cells] using the expression vector pECE_Flag-SIRT1 from 
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addgene (plasmid 1791; [35]). Lysates of cells transfected with the empty vector pECE (mock-
control) (1) or pECE Flag-SIRT1 vector (2) were used for Western Blot analysis. B) mock-
transfected (mock-control) and Flag-SIRT1 transfected HepG2 cells were stimulated with 
resveratrol [50, 100µM Resv.] for 24h and Western Blot analysis of acetylated p53 (K382), p21 and 
GAPDH was performed. Densitometric anaylsis of acetylated p53 of three independent Western 
Blots is shown. Data were normalised to non-transfected HepG2 cells stimulated with resveratrol 
alone which was set 1. C) To analyse the effect of SIRT1 overexpression on resveratrol-induced 
NAMPT release, supernatant of mock-transfected and Flag-SIRT1 transfected HepG2 cells 
stimulated with or without resveratrol [100µM] were used to measure eNAMPT level. One 
representative Western blot out of 3 independent experiments is shown. D) Cell viability of mock-
transfected and Flag-SIRT1 transfected HepG2 cells treated with resveratrol [100µM] (black bars) 
was measured using WST-1 assay (n=3). Data were normalised to untreated mock-control which 
was set 1. E) mock-transfected (white bars) and Flag-SIRT1 transfected HepG2 cells (black bars) 
were stimulated with resveratrol [25, 50µM] for 24h. Percentage of cells in the S-phase were 
measured by PI staining and FACS analysis. All data are shown as mean± SEM (n=4). The 
difference between two groups was evaluated using unpaired Student’s t-test (##p<0.01 mock-
transfected cells compared to mock-transfected cells treated with resveratrol (white bars, mock-
control), **p<0.01, ***p< 0.001 Flag-SIRT1 transfected cells treated with resveratrol (black bars) 
compared to resveratrol-treated mock-transfected cells (white bars). 
 
4.4 Discussion 
There is growing in vitro and in vivo evidence demonstrating the inhibitory effects of 
resveratrol on liver cancer [44–46]. It is known that resveratrol affects numerous signal 
transduction pathways associated with tumorigenesis [47]. However, the mechanisms how 
resveratrol selectively modulates proliferation and apoptosis in tumor cells are not fully 
understood. A recent study demonstrated that resveratrol has the chemical structure to 
inhibit the activity of different human histone deacetylases (HDACs), important 
transcriptional and post-translational regulators [48]. We investigated the molecular 
mechanisms of resveratrol-induced reduction of cell viability in human hepatocellular 
carcinoma cells and compared the results with non-cancerous primary human hepatocytes. 
We found that resveratrol selectively induced apoptosis in HepG2 and Hep3B cells, but 
not in primary hepatocytes. Our data confirm the apoptotic effects of resveratrol on 
hepatocarcinoma cells independent of p53 function. Furthermore, several other studies 
reported that resveratrol induced p53-independent apoptosis in tumor cells [49,50], 
indicating that p53 is not an absolute requirement for the apoptotic effect of resveratrol. In 
contrast,  we found an arrest of cells in the S- and G2/M-phase of the cell cycle only in p53 
wild-type HepG2 cells and not in Hep3B cells lacking p53, which was also shown by other 
groups [7,51,52].  
Our study revealed that NAMPT and SIRT1 were expressed in an opposite way in 
hepatocarcinoma cells and primary hepatocytes and were differentially regulated by 
resveratrol. Other groups found SIRT1 expression to be significantly elevated in 
hepatocellular carcinoma (HCC) compared to non-cancerous tissues, the expression levels 
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correlated with tumor grades and predicted poor prognosis. SIRT1 was shown to promote 
tumorigenesis in HCC, and inhibition of SIRT1 consistently suppressed the proliferation of 
HCC cells in vitro or in vivo via the induction of cellular senescence or apoptosis [53–56]. 
The expression and role of NAMPT in HCC has not been characterised so far. In contrast 
to findings in other cancer cell types [18], we found that hepatocarcinoma cells express 
lower levels of NAMPT compared to non-cancerous primary hepatocytes. However, we 
found that HepG2 cells possess a higher basal NAMPT activity than primary hepatocytes, 
which goes in line with the comparable NAD levels in both cell types despite weaker 
NAMPT expression in hepatocarcinoma cells.  
Under basal conditions primary hepatocytes released higher amounts of NAMPT 
into the supernatant than HepG2 cells. As shown by our group, HepG2 cells and primary 
human hepatocytes constitutively release NAMPT in its dimeric, enzymatically active form 
[43]. Presumably, due to the higher amount of cellular NAMPT protein in primary human 
hepatocytes compared to hepatocarcinoma cells, NAMPT is constitutively more released 
from primary hepatocytes leading to higher basal eNAMPT level. However, we cannot 
completely preclude, that due to necrosis of fragile or dead primary hepatocytes, proteins 
are released into the supernatant.  
There are several reports showing that resveratrol acts as a natural SIRT1 activator 
[10,57–60]. We observed increased NAMPT activity and intracellular NAD levels in 
primary hepatocytes providing evidence for resveratrol as SIRT1 activator in non-
cancerous cells. However, recent data showed that resveratrol is not a direct activator of 
SIRT1 and therefore some mediators are may be involved in this interplay [48,61–63]. 
Moreover, little is known about NAMPT and SIRT1 regulation by resveratrol in cancer 
cells. A recent report showed that SIRT1 inhibition is involved in resveratrol-induced cell 
death in Hodgkin lymphoma (HL)-derived L-428 cells [11]. Additionally, neuroblastoma 
cells treated with resveratrol also underwent apoptosis and showed a downregulaton of 
SIRT1 [64]. In our study, resveratrol-stimulated HepG2 cells showed similar responses like 
cells treated with the SIRT1 inhibitor EX527. Thus, we assume that resveratrol is rather 
acting as a NAMPT and SIRT1 inhibitor in hepatocarcinoma cells. However, there are 
several reports demonstrating other mechanisms leading to p53 acetylation by resveratrol 
[65,66]. 
Our findings indicate that NMN did not ameliorate resveratrol-induced effects on 
apoptosis, cell cycle arrest and NAMPT release, suggesting that the availability of NAD is 
not a limiting factor in this scenario. A variety of posttranslational modifications in SIRT1 
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N- and C-terminal extensions have been reported, effecting SIRT1 enzyme activity and 
protein interactions [67,68]. Our findings raise the possibility that, in some cases, the 
regulation of SIRT1 by other proteins may be more important than NAD availability. 
Increase in p53 transcriptional activity and induction of S-phase arrest observed upon 
treatment with resveratrol were abrogated upon SIRT1 overexpression. However, SIRT1 
overexpression was not able to augment reduced cell viability in HepG2 cells under high 
resveratrol concentrations. Resveratrol affects a multitude of other signal transduction 
pathways associated with apoptotic mechanisms and transcriptional regulation [66,69] that 
are still activated and not SIRT1 dependent [64]. Thus, these collective activities, rather 
than just a single effect, may account for the anticancer properties of resveratrol. However, 
our data give evidence that resveratrol regulates NAMPT activity in cancer cells and non-
cancerous cells. Resveratrol could regulate NAMPT enzymatic activity by at least two 
hypothetical mechanisms: i) by direct interaction inducing conformational changes that lead 
to alterations of enzymatic activity, or ii) by inducing a posttranslational modification of 
NAMPT.  Our study revealed that SIRT1 inhibition downregulates NAMPT activity and 
induces NAMPT secretion. This provides the basis for further mechanistic studies on 
NAMPT-SIRT1 interaction and their regulation. 
Further, we found a time- and dose-dependent NAMPT release after resveratrol 
stimulation of HepG2 cells which was associated with increased NAMPT mRNA 
expression. The association of increased NAMPT release and mRNA expression has also 
been shown by Kover et al. in human islets [70]. eNAMPT has been described to act as a 
cytokine (as pre-B cell colony enhancing factor, PBEF)[71] or as an adipokine 
(visfatin)[72,73] but also has extracellular enzymatic function to yield NMN [74]. To our 
knowledge, for the first time our data point to SIRT1 as regulator of NAMPT secretion 
and NAMPT enzymatic activity in the supernatant. We could show that the resveratrol-
induced NAMPT release was significantly reduced after SIRT1 overexpression, indicating a 
crucial role for SIRT1 in resveratrol-mediated NAMPT secretion. 
In summary, our study revealed that resveratrol selectively induced p53-
independent cell death in hepatocarcinoma cells and differentially regulated NAMPT and 
SIRT1 in cancer cells and non-cancerous cells. Our data give evidence that in contrast to 
normal hepatocytes, resveratrol does not act as a NAMPT and SIRT1 activator in 
hepatocarcinoma cells. However, it remains to be investigated whether NAMPT interacts 
with SIRT1 and how it is regulated by resveratrol or other mediators and linked to cellular 
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metabolism and apoptosis. This will provide novel insights concerning the potential of 
NAMPT and SIRT1 as therapeutic targets in hepatocellular carcinoma. 
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4.6 Supplementary Material 
 
Figure S1. Establishment of parameters for a NAMPT enzymatic assay. Assay conditions, 
such as A) protein amount, B) pH value and C) incubation time were optimized for measuring 
NAMPT enzymatic activity. D) We validated the assay performance by adding the specific 
NAMPT inhibitor FK866 to the lysate before measuring NAMPT activity. As expected, FK866 
induced a dose-dependent decrease in NAMPT activity with an IC50 value of 8.2 nM. Experiments 
were performed in HepG2 cells. Data are presented as mean± SEM. 
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Figure S2. Cell cycle arrest in Hep3B and a representative dot plot of HepG2 cells. A) PI 
staining of cell cycle distribution of Hep3B cells (n=2) stimulated with different concentration of 
resveratrol [25/50/100µM] for 24h. B) A representative dot plot of cell cycle analysis of HepG2 
cells. The left plot shows pulse width versus area; this is the plot used to distinguish between single 
cells and aggregates. Single cells have been gated and a FL2-Area histogram has been drawn and 
formatted to show only the events inside of the single cell region. 
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Figure S3. Resveratrol does not have cytotoxic effects on HepG2 cells and primary human 
hepatocytes. HepG2 cells and primary human hepatocytes were stimulated with resveratrol 
[10/25/50/100µM] in serum-free medium for 24h and supernatant was used for the ToxiLight 
Non-destructive Cytotoxicity BioAssay. A) Primary human hepatocytes (n=3) and B) HepG2 cells 
(n=3) showed no cytotoxic effects after stimulation with resveratrol. Data are shown as mean± 
SEM. Statistical analysis was performed using one-way ANOVA and the Bonferroni post hoc test 
(n.s. not significant). C) Supernatants of resveratrol [100µM] or serum-free medium (con) treated 
HepG2 cells after 6, 12 and 24h were used to measure extracellular NAMPT levels by Western 
Blot. 
 
Figure S4. Resveratrol downregulates NAMPT enzymatic activity in Hep3B cells. Hep3B 
cells were stimulated with resveratrol [10/25/50/100µM] in serum-free medium for 24h. NAMPT 
enzymatic activity was measured by the conversion of 14C- labelled nicotinamide to 14C-NMN (see 
Material and Methods). Counts (cpm) were normalised to µg total protein in each sample measured 
by BCA protein assay. Data are represented as mean± SEM and statistical analysis was performed 
using one-way ANOVA and the Bonferroni post hoc test (*p< 0.05).  
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Figure S5. p21 and Bax expression in HepG2 cells and primary human hepatocytes. HepG2 
cells and primary human hepatocytes were stimulated with resveratrol [10/25/50/100µM] in 
serum-free medium (0) for 24h. p21 mRNA expression in A) HepG2 cells (n=3) and B) primary 
human hepatocytes (n=4). C) Lysates of HepG2 cells (n=3) were used for Western Blot analysis of 
Bax protein expression. GAPDH was used as loading control. One representative blot out of 3 
independent experiments is shown. 
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Figure S6. NMN does not ameliorate resveratrol-mediated effects on cell viability, NAMPT 
activity, NAMPT release and p53 hyperacetylation. Given that resvertarol down-regulates 
NAMPT and increases p53 acetylation in hepatocarcinoma cells which was absent in primary 
hepatocytes we hypothesised that the administration of NMN, the reaction product of NAMPT 
and a precursor of NAD, is able to ameliorate the resveratrol-mediated effects by increasing SIRT1 
activity. At the beginning, we tested whether HepG2 cells are able to utilize exogenous NMN 
[500µM] and to synthesize NAD. Therefore, we stimulated the cells with FK866 [10nM] to inhibit 
NAMPT activity and co-stimulated the cells with NMN [500µM]. We could show that FK866 
depleted the intracellular NAD levels by -79.4±3.3% in HepG2 cells which could be restored by 
NMN supplementation. A) NAD levels of HepG2 cells (n=5) treated with the NAMPT inhibitor 
FK866 [10nM] (white bars) in serum-free medium (con) and NMN [500µM] (black bars) for 24h. 
Annexin V/PI apoptosis assay of B) HepG2 cells (n=3) and C) Hep3B cells (n=2) treated with 
resveratrol [25/50/100µM] in serum-free medium and co-stimulated with NMN [500µM] for 24h. 
An+ and An+/PI+ cells were considered apoptotic. Data are represented as mean± SEM. 
Differences between two groups were evaluated using unpaired Student’s t-test (resvertarol (white 
bar) compared to resveratrol +NMN (black bar)). Then D) Western Blot analysis of cleaved 
caspase-3, E) acetylated p53 (K382) and F) eNAMPT levels in supernatant of these cells were 
performed. One representative blot out of at least 3 independent experiments is shown.  
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